Generation	O
of	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
against	O
immunorecessive	B-protein
epitopes	I-protein
after	O
multiple	O
immunizations	O
with	O
adenovirus	O
vectors	O
is	O
dependent	O
on	O
haplotype	O
.	O

Currently	O
,	O
adenovirus	O
(	O
Ad	O
)	O
is	O
being	O
considered	O
as	O
a	O
vector	O
for	O
the	O
treatment	O
of	O
cystic	O
fibrosis	O
as	O
well	O
as	O
other	O
diseases	O
.	O

However	O
,	O
the	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocyte	I-cell_type
(	O
CTL	B-cell_type
)	O
response	O
to	O
Ad	O
could	O
limit	O
the	O
effectiveness	O
of	O
such	O
approaches	O
.	O

Since	O
the	O
CTL	B-cell_type
response	O
to	O
virus	O
infection	O
is	O
often	O
focused	O
on	O
one	O
or	O
a	O
few	O
immunodominant	B-protein
epitopes	I-protein
,	O
one	O
approach	O
to	O
circumvent	O
this	O
response	O
is	O
to	O
create	O
vectors	O
that	O
lack	O
these	O
immunodominant	B-protein
epitopes	I-protein
.	O

The	O
effectiveness	O
of	O
this	O
approach	O
was	O
tested	O
by	O
immunizing	O
mice	O
with	O
human	O
group	O
C	O
adenoviruses	O
.	O

Three	O
mouse	O
strains	O
(	O
C57BL/10SnJ	O
[	O
H-2b	O
]	O
,	O
C3HeB/FeJ	O
[	O
H-2k	O
]	O
,	O
and	O
BALB/cByJ	O
[	O
H-2d	O
]	O
)	O
were	O
immunized	O
with	O
wild-type	O
Ad	O
or	O
Ad	O
vectors	O
lacking	O
the	O
immunodominant	B-protein
antigen	I-protein
(	O
s	O
)	O
,	O
and	O
the	O
CTL	B-cell_type
responses	O
were	O
measured	O
.	O

In	O
C57BL/10	O
(	O
B10	O
)	O
mice	O
,	O
a	O
single	O
inoculation	O
intraperitoneally	O
(	O
i.p.	O
)	O
led	O
to	O
the	O
recognition	O
of	O
an	O
immunodominant	B-protein
antigen	I-protein
in	O
E1A	B-DNA
.	O

When	O
B10	O
mice	O
were	O
inoculated	O
multiple	O
times	O
either	O
i.p	O
.	O

or	O
intranasally	O
with	O
wild-type	O
Ad	O
or	O
an	O
Ad	O
vector	O
lacking	O
most	O
of	O
the	O
E1	B-DNA
region	I-DNA
,	O
subdominant	O
epitopes	O
outside	O
this	O
region	O
were	O
recognized	O
.	O

In	O
contrast	O
,	O
C3H	O
mice	O
inoculated	O
with	O
wild-type	O
Ad	O
recognized	O
an	O
epitope	O
mapping	O
within	O
E1B	B-DNA
.	O
When	O
inoculated	O
twice	O
with	O
Ad	O
vectors	O
lacking	O
both	O
E1A	B-DNA
and	O
E1B	B-DNA
,	O
no	O
immunorecessive	B-protein
epitopes	I-protein
were	O
recognized	O
.	O

The	O
immune	O
response	O
to	O
Ad	O
in	O
BALB/c	O
mice	O
was	O
more	O
complex	O
.	O

CTLs	B-cell_type
from	O
BALB/c	O
mice	O
inoculated	O
i.p.	O
with	O
wild-type	O
Ad	O
recognized	O
E1B	B-DNA
in	O
the	O
context	O
of	O
the	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
I	I-DNA
Dd	I-DNA
allele	I-DNA
and	O
a	O
region	O
outside	O
E1	B-DNA
associated	O
with	O
the	O
Kd	B-DNA
allele	I-DNA
.	O

When	O
BALB/c	O
mice	O
were	O
inoculated	O
with	O
E1	B-DNA
-deleted	O
Ad	O
vectors	O
,	O
only	O
the	O
immunodominant	B-protein
Kd-restricted	I-protein
epitope	I-protein
was	O
recognized	O
,	O
and	O
Dd-restricted	O
CTLs	B-cell_type
did	O
not	O
develop	O
.	O

This	O
report	O
indicates	O
that	O
the	O
emergence	O
of	O
CTLs	B-cell_type
against	O
immunorecessive	B-protein
epitopes	I-protein
following	O
multiple	O
administrations	O
of	O
Ad	O
vectors	O
lacking	O
immunodominant	O
antigens	O
is	O
dependent	O
on	O
haplotype	O
and	O
could	O
present	O
an	O
obstacle	O
to	O
gene	O
therapy	O
in	O
an	O
MHC	B-protein
-diverse	O
human	O
population	O
.	O

JOURNAL	NULL
OF	NULL
ViroLOGYy	NULL
,	NULL
Mar	NULL
.	NULL

1997	NULL
,	NULL
p.	NULL
2277-2284	NULL
0022-538X	NULL
,	NULL
/97/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
Â©	NULL
1997	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

71	NULL
,	NULL
No	NULL
.	NULL

3	NULL
Generation	NULL
of	NULL
Cytotoxic	NULL
T	NULL
Lymphocytes	NULL
against	NULL
Immunorecessive	NULL
Epitopes	NULL
after	NULL
Multiple	NULL
Immunizations	NULL
with	NULL
Adenovirus	NULL
Vectors	NULL
Is	NULL
Dependent	NULL
on	NULL
Haplotype	NULL
TIM	NULL
E.	NULL
SPARER	NULL
,	NULL
``	NULL
SUSAN	NULL
G.	NULL
WYNN	NULL
,	NULL
'	NULL
DANIEL	NULL
J.	NULL
CLARK	NULL
,	NULL
``	NULL
JOHANNE	NULL
M.	NULL
KAPLAN	NULL
,	NULL
``	NULL
LISA	NULL
M.	NULL
CARDOZA	NULL
,	NULL
*	NULL
SAMUEL	NULL
C.	NULL
WADSWORTH	NULL
,	NULL
``	NULL
ALAN	NULL
E.	NULL
SMITH	NULL
,	NULL
``	NULL
anp	NULL
LINDA	NULL
R.	NULL
GOODING'*	NULL
Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Immunology	NULL
,	NULL
Emory	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Atlanta	NULL
,	NULL
Georgia	NULL
30322	NULL
,	NULL
``	NULL
and	NULL
Genzyme	NULL
Corporation	NULL
,	NULL
Framingham	NULL
,	NULL
Massachusetts	NULL
017012	NULL
Received	NULL
1	NULL
May	NULL
1996/Accepted	NULL
9	NULL
December	NULL
1996	NULL
Currently	NULL
,	NULL
adenovirus	NULL
(	NULL
Ad	NULL
)	NULL
is	NULL
being	NULL
considered	NULL
as	NULL
a	NULL
vector	NULL
for	NULL
the	NULL
treatment	NULL
of	NULL
cystic	NULL
fibrosis	NULL
as	NULL
well	NULL
as	NULL
other	NULL
diseases	NULL
.	NULL

However	NULL
,	NULL
the	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
(	NULL
CTL	NULL
)	NULL
response	NULL
to	NULL
Ad	NULL
could	NULL
limit	NULL
the	NULL
effectiveness	NULL
of	NULL
such	NULL
approaches	NULL
.	NULL

Since	NULL
the	NULL
CTL	NULL
response	NULL
to	NULL
virus	NULL
infection	NULL
is	NULL
often	NULL
focused	NULL
on	NULL
one	NULL
or	NULL
a	NULL
few	NULL
immunodominant	NULL
epitopes	NULL
,	NULL
one	NULL
approach	NULL
to	NULL
circumvent	NULL
this	NULL
response	NULL
is	NULL
to	NULL
create	NULL
vectors	NULL
that	NULL
lack	NULL
these	NULL
immunodominant	NULL
epitopes	NULL
.	NULL

The	NULL
effectiveness	NULL
of	NULL
this	NULL
approach	NULL
was	NULL
tested	NULL
by	NULL
immunizing	NULL
mice	NULL
with	NULL
human	NULL
group	NULL
C	NULL
adenoviruses	NULL
.	NULL

Three	NULL
mouse	NULL
strains	NULL
(	NULL
C57BL/108nJ	NULL
[	NULL
H-Zb	NULL
]	NULL
,	NULL
C3HeB/FeJ	NULL
[	NULL
H-Zk	NULL
]	NULL
,	NULL
and	NULL
BALB/cByJ	NULL
[	NULL
H-Zd	NULL
]	NULL
)	NULL
were	NULL
immunized	NULL
with	NULL
wild-type	NULL
Ad	NULL
or	NULL
Ad	NULL
vectors	NULL
lacking	NULL
the	NULL
immunodominant	NULL
antigen	NULL
(	NULL
s	NULL
)	NULL
,	NULL
and	NULL
the	NULL
CTL	NULL
responses	NULL
were	NULL
measured	NULL
.	NULL

In	NULL
C57BL/10	NULL
(	NULL
B10	NULL
)	NULL
mice	NULL
,	NULL
a	NULL
single	NULL
inoculation	NULL
intraperitoneally	NULL
(	NULL
i.p	NULL
.	NULL
)	NULL

led	NULL
to	NULL
the	NULL
recognition	NULL
of	NULL
an	NULL
immunodominant	NULL
antigen	NULL
in	NULL
E1A	NULL
.	NULL

When	NULL
B10	NULL
mice	NULL
were	NULL
inoculated	NULL
multiple	NULL
times	NULL
either	NULL
i.p	NULL
.	NULL

or	NULL
intranasally	NULL
with	NULL
wild-type	NULL
Ad	NULL
or	NULL
an	NULL
Ad	NULL
vector	NULL
lacking	NULL
most	NULL
of	NULL
the	NULL
E1	NULL
region	NULL
,	NULL
subdominant	NULL
epitopes	NULL
outside	NULL
this	NULL
region	NULL
were	NULL
recognized	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
C3H	NULL
mice	NULL
inoculated	NULL
with	NULL
wild-type	NULL
Ad	NULL
recognized	NULL
an	NULL
epitope	NULL
mapping	NULL
within	NULL
E1B	NULL
.	NULL

When	NULL
inoculated	NULL
twice	NULL
with	NULL
Ad	NULL
vectors	NULL
lacking	NULL
both	NULL
E1A	NULL
and	NULL
E1B	NULL
,	NULL
no	NULL
immunorecessive	NULL
epitopes	NULL
were	NULL
recognized	NULL
.	NULL

The	NULL
immune	NULL
response	NULL
to	NULL
Ad	NULL
in	NULL
BALB/c	NULL
mice	NULL
was	NULL
more	NULL
complex	NULL
.	NULL

CTLs	NULL
from	NULL
BALB/c	NULL
mice	NULL
inoculated	NULL
i.p	NULL
.	NULL

with	NULL
wild-type	NULL
Ad	NULL
recognized	NULL
E1B	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
major	NULL
histocompatibility	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
class	NULL
I	NULL
D	NULL
``	NULL
allele	NULL
and	NULL
a	NULL
region	NULL
outside	NULL
E1	NULL
associated	NULL
with	NULL
the	NULL
K	NULL
``	NULL
allele	NULL
.	NULL

When	NULL
BALB/c	NULL
mice	NULL
were	NULL
inoculated	NULL
with	NULL
El-deleted	NULL
Ad	NULL
vectors	NULL
,	NULL
only	NULL
the	NULL
immunodominant	NULL
K	NULL
``	NULL
-restricted	NULL
epitope	NULL
was	NULL
recognized	NULL
,	NULL
and	NULL
D'-restricted	NULL
CTLs	NULL
did	NULL
not	NULL
develop	NULL
.	NULL

This	NULL
report	NULL
indicates	NULL
that	NULL
the	NULL
emergence	NULL
of	NULL
CTLs	NULL
against	NULL
immunorecessive	NULL
epitopes	NULL
following	NULL
multiple	NULL
administrations	NULL
of	NULL
Ad	NULL
vectors	NULL
lacking	NULL
immunodominant	NULL
antigens	NULL
is	NULL
dependent	NULL
on	NULL
haplotype	NULL
and	NULL
could	NULL
present	NULL
an	NULL
obstacle	NULL
to	NULL
gene	NULL
therapy	NULL
in	NULL
an	NULL
MHC-diverse	NULL
human	NULL
population	NULL
.	NULL

CD8	NULL
*	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
(	NULL
CTL	NULL
)	NULL
are	NULL
important	NULL
for	NULL
viral	NULL
clearance	NULL
in	NULL
many	NULL
virus	NULL
systems	NULL
(	NULL
for	NULL
a	NULL
review	NULL
,	NULL
see	NULL
reference	NULL
8	NULL
)	NULL
.	NULL

CTL	NULL
recognize	NULL
major	NULL
histocompatibility	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
class	NULL
I	NULL
molecules	NULL
bound	NULL
to	NULL
peptides	NULL
of	NULL
8	NULL
to	NULL
10	NULL
residues	NULL
in	NULL
length	NULL
derived	NULL
from	NULL
endogenously	NULL
synthesized	NULL
proteins	NULL
(	NULL
36	NULL
)	NULL
.	NULL

In	NULL
spite	NULL
of	NULL
the	NULL
hundreds	NULL
of	NULL
potential	NULL
antigens	NULL
that	NULL
could	NULL
be	NULL
recognized	NULL
by	NULL
class	NULL
I-restricted	NULL
CTL	NULL
during	NULL
a	NULL
viral	NULL
infection	NULL
,	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
is	NULL
focused	NULL
on	NULL
only	NULL
one	NULL
or	NULL
a	NULL
few	NULL
immunodominant	NULL
antigens	NULL
.	NULL

For	NULL
example	NULL
,	NULL
even	NULL
though	NULL
influenza	NULL
virus	NULL
and	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
produce	NULL
complex	NULL
proteins	NULL
such	NULL
as	NULL
hemagglutinin	NULL
or	NULL
gp160	NULL
with	NULL
multiple	NULL
potential	NULL
CTL	NULL
epitopes	NULL
,	NULL
the	NULL
CTL	NULL
response	NULL
is	NULL
dominated	NULL
by	NULL
a	NULL
few	NULL
immunodominant	NULL
epitopes	NULL
(	NULL
3	NULL
,	NULL
33	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
the	NULL
mouse	NULL
CTL	NULL
responses	NULL
to	NULL
the	NULL
708-amino-acid	NULL
T	NULL
antigen	NULL
of	NULL
simian	NULL
virus	NULL
40	NULL
(	NULL
SV40	NULL
)	NULL
are	NULL
focused	NULL
on	NULL
one	NULL
to	NULL
three	NULL
epitopes	NULL
that	NULL
vary	NULL
with	NULL
the	NULL
major	NULL
histocompatibility	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
class	NULL
I	NULL
allele	NULL
(	NULL
28	NULL
,	NULL
34	NULL
)	NULL
.	NULL

gleccntly	NULL
,	NULL
the	NULL
immune	NULL
response	NULL
to	NULL
adenovirus	NULL
(	NULL
Ad	NULL
)	NULL
has	NULL
become	NULL
increasingly	NULL
important	NULL
because	NULL
Ad	NULL
is	NULL
being	NULL
examined	NULL
as	NULL
a	NULL
vector	NULL
for	NULL
in	NULL
vivo	NULL
gene	NULL
therapy	NULL
.	NULL

Genes	NULL
inserted	NULL
into	NULL
El-deficient	NULL
(	NULL
AE1A	NULL
and	NULL
E1B	NULL
)	NULL
Ads	NULL
are	NULL
being	NULL
tested	NULL
for	NULL
various	NULL
gene	NULL
therapy	NULL
applications	NULL
,	NULL
including	NULL
replacement	NULL
of	NULL
defective	NULL
tumor	NULL
suppressor	NULL
genes	NULL
in	NULL
some	NULL
cancers	NULL
(	NULL
6	NULL
)	NULL
,	NULL
the	NULL
low	NULL
density	NULL
lipoprotein	NULL
receptor	NULL
gene	NULL
in	NULL
familial	NULL
hypercholesterolemia	NULL
patients	NULL
(	NULL
17	NULL
)	NULL
,	NULL
and	NULL
the	NULL
cystic	NULL
fibrosis	NULL
transmembrane	NULL
conductance	NULL
*	NULL
Corresponding	NULL
Address	NULL
:	NULL
Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Immunology	NULL
,	NULL
Emory	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
3107	NULL
Rollins	NULL
Research	NULL
Building	NULL
,	NULL
1510	NULL
Clifton	NULL
Rd	NULL
.	NULL

,	NULL
Atlanta	NULL
,	NULL
GA	NULL
30322	NULL
.	NULL

2277	NULL
regulator	NULL
(	NULL
CFTR	NULL
)	NULL
gene	NULL
in	NULL
cystic	NULL
fibrosis	NULL
patients	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Although	NULL
successful	NULL
Ad-mediated	NULL
gene	NULL
transfer	NULL
of	NULL
CFTR	NULL
has	NULL
been	NULL
reported	NULL
both	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
(	NULL
37	NULL
,	NULL
43	NULL
,	NULL
44	NULL
)	NULL
immuno-logical	NULL
responses	NULL
to	NULL
Ad	NULL
vectors	NULL
may	NULL
limit	NULL
their	NULL
usefulness	NULL
.	NULL

Yang	NULL
et	NULL
al	NULL
.	NULL

(	NULL
39	NULL
,	NULL
40	NULL
)	NULL
reported	NULL
that	NULL
the	NULL
CTL	NULL
response	NULL
to	NULL
Ad	NULL
contributes	NULL
to	NULL
the	NULL
elimination	NULL
of	NULL
transgene	NULL
expression	NULL
in	NULL
vivo	NULL
.	NULL

CTL	NULL
recognizing	NULL
viral	NULL
proteins	NULL
could	NULL
eliminate	NULL
the	NULL
cells	NULL
expressing	NULL
the	NULL
transgene	NULL
product	NULL
,	NULL
thereby	NULL
requiring	NULL
readminis-tration	NULL
of	NULL
the	NULL
Ad	NULL
vector	NULL
.	NULL

If	NULL
this	NULL
is	NULL
the	NULL
case	NULL
,	NULL
then	NULL
preventing	NULL
recognition	NULL
of	NULL
the	NULL
Ad	NULL
vector	NULL
by	NULL
CTL	NULL
would	NULL
allow	NULL
for	NULL
longer	NULL
intervals	NULL
between	NULL
vector	NULL
readministrations	NULL
.	NULL

Thus	NULL
,	NULL
an	NULL
understanding	NULL
of	NULL
the	NULL
CTL	NULL
response	NULL
to	NULL
Ad	NULL
might	NULL
provide	NULL
useful	NULL
information	NULL
for	NULL
the	NULL
future	NULL
design	NULL
of	NULL
Ad	NULL
vectors	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
revealed	NULL
that	NULL
when	NULL
CTL	NULL
are	NULL
generated	NULL
against	NULL
wild-type	NULL
Ad	NULL
,	NULL
they	NULL
recognize	NULL
E1A	NULL
as	NULL
the	NULL
immunodominant	NULL
antigen	NULL
in	NULL
B10	NULL
mice	NULL
but	NULL
not	NULL
in	NULL
C3H	NULL
or	NULL
BALB/c	NULL
mice	NULL
(	NULL
27	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
set	NULL
out	NULL
to	NULL
determine	NULL
whether	NULL
multiple	NULL
immunizations	NULL
altered	NULL
the	NULL
CTL	NULL
response	NULL
and	NULL
whether	NULL
the	NULL
CTL	NULL
response	NULL
differed	NULL
after	NULL
intranasal	NULL
(	NULL
i.n	NULL
.	NULL
)	NULL

versus	NULL
intraperitoneal	NULL
(	NULL
i.p	NULL
.	NULL
)	NULL

inoculations	NULL
,	NULL
as	NULL
well	NULL
as	NULL
to	NULL
identify	NULL
the	NULL
immunodominant	NULL
antigens	NULL
recognized	NULL
by	NULL
C3H	NULL
and	NULL
BALB/c	NULL
mice	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cells	NULL
and	NULL
viruses	NULL
.	NULL

SV40-transformed	NULL
fibroblasts	NULL
(	NULL
SVB6KHA	NULL
from	NULL
C57/BL6	NULL
mice	NULL
,	NULL
SV2R	NULL
from	NULL
B10.A	NULL
(	NULL
2R	NULL
)	NULL
mice	NULL
,	NULL
PSC3H	NULL
from	NULL
C3HeJ	NULL
mice	NULL
,	NULL
SVBALB	NULL
from	NULL
BALB/c	NULL
mice	NULL
,	NULL
SVHTI	NULL
from	NULL
HTI	NULL
mice	NULL
,	NULL
and	NULL
SVHTG	NULL
from	NULL
HTG	NULL
mice	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
3	NULL
,	NULL
14	NULL
,	NULL
29	NULL
]	NULL
)	NULL
were	NULL
grown	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
(	NULL
GIBCO	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
N.Y.	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
Hyclone	NULL
,	NULL
Logan	NULL
,	NULL
Utah	NULL
)	NULL
and	NULL
1	NULL
%	NULL
1-glutamine	NULL
(	NULL
GIBCO	NULL
)	NULL
.	NULL

Viruses	NULL
were	NULL
grown	NULL
on	NULL
KB	NULL
cells	NULL
and	NULL
plagued	NULL
on	NULL
A549	NULL
cells	NULL
(	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
[	NULL
ATCC	NULL
]	NULL
,	NULL
2278	NULL
SPARER	NULL
ET	NULL
AL	NULL
.	NULL

E1A/E1B	NULL
Map	NULL
Nucleotides	NULL
soo	NULL
1000	NULL
1800	NULL
2000	NULL
2sco	NULL
asoo	NULL
Â«	NULL
000	NULL
L	NULL
1	NULL
|	NULL
|	NULL
1	NULL
|	NULL
|	NULL
|	NULL
Proteins	NULL
:	NULL
E1A	NULL
E1B	NULL
sso	NULL
ara	NULL
-	NULL
deze	NULL
-	NULL
1540	NULL
2016	NULL
55K	NULL
sso1	NULL
--	NULL
A	NULL
El	NULL
f	NULL
u	NULL
I	NULL
x	NULL
|	NULL
I	NULL
(	NULL
17K	NULL
geo	NULL
gra	NULL
rng	NULL
1540	NULL
ste	NULL
.	NULL

goss	NULL
sere	NULL
.	NULL

asor	NULL
I	NULL
by	NULL
'	NULL
ICCL	NULL
0	NULL
use*	NULL
|	NULL
14K	NULL
(	NULL
Protein	NULL
IX	NULL
)	NULL
iz	NULL
|	NULL
2ese	NULL
s609	NULL
4070	NULL
E1A	NULL
Mutants	NULL
46	NULL
1349	NULL
5	NULL
&	NULL
9	NULL
di313	NULL
E1B	NULL
Mutants	NULL
E	NULL
4020	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

E1A/E1B	NULL
mutants	NULL
used	NULL
in	NULL
this	NULL
study	NULL
.	NULL

The	NULL
Ad	NULL
nucleotide	NULL
map	NULL
of	NULL
E1A/E1B	NULL
is	NULL
shown	NULL
at	NULL
the	NULL
top	NULL
.	NULL

Open	NULL
boxes	NULL
,	NULL
proteins	NULL
;	NULL
filled	NULL
boxes	NULL
,	NULL
deletions	NULL
.	NULL

The	NULL
nucleotides	NULL
deleted	NULL
in	NULL
each	NULL
mutant	NULL
are	NULL
noted	NULL
.	NULL

The	NULL
E1A/E1B	NULL
mutants	NULL
are	NULL
d/312	NULL
(	NULL
A448-1349	NULL
)	NULL
,	NULL
di313	NULL
(	NULL
A1334-3639	NULL
)	NULL
(	NULL
18	NULL
)	NULL
,	NULL
Ad2/CFTR-2	NULL
(	NULL
A357-3328	NULL
)	NULL
(	NULL
2	NULL
)	NULL
,	NULL
and	NULL
Ad	NULL
?	NULL

2/	NULL
CFTR-7	NULL
(	NULL
A545-4020	NULL
)	NULL
(	NULL
this	NULL
study	NULL
)	NULL
.	NULL

Rockville	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

,	NULL
except	NULL
for	NULL
viruses	NULL
lacking	NULL
E1A	NULL
and/or	NULL
E1B	NULL
,	NULL
which	NULL
were	NULL
grown	NULL
and	NULL
plaqued	NULL
on	NULL
293	NULL
cells	NULL
(	NULL
ATCC	NULL
)	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
16	NULL
)	NULL
.	NULL

The	NULL
virus	NULL
mutants	NULL
used	NULL
in	NULL
this	NULL
study	NULL
are	NULL
summarized	NULL
in	NULL
Fig	NULL
1.	NULL
dI801	NULL
(	NULL
4	NULL
)	NULL
is	NULL
an	NULL
Ad	NULL
type	NULL
2	NULL
(	NULL
Ad2	NULL
)	NULL
-based	NULL
mutant	NULL
that	NULL
lacks	NULL
most	NULL
of	NULL
E3	NULL
but	NULL
retains	NULL
14.7K	NULL
.	NULL

d1309	NULL
(	NULL
18	NULL
)	NULL
is	NULL
an	NULL
Ad5	NULL
virus	NULL
lacking	NULL
the	NULL
E3	NULL
proteins	NULL
10.4K	NULL
,	NULL
14.5K	NULL
,	NULL
and	NULL
14.7K	NULL
but	NULL
maintaining	NULL
E3	NULL
gp19K	NULL
.	NULL

4/327	NULL
(	NULL
35	NULL
)	NULL
is	NULL
deleted	NULL
for	NULL
almost	NULL
the	NULL
entire	NULL
E3	NULL
region	NULL
including	NULL
gp19K	NULL
.	NULL

41754	NULL
(	NULL
15	NULL
)	NULL
lacks	NULL
only	NULL
gp19K	NULL
and	NULL
part	NULL
of	NULL
6.7K	NULL
.	NULL

Ad2/CFTR-2	NULL
is	NULL
a	NULL
recombinant	NULL
Ad2	NULL
vector	NULL
in	NULL
which	NULL
most	NULL
of	NULL
the	NULL
E1	NULL
region	NULL
(	NULL
nucleotides	NULL
357	NULL
to	NULL
3328	NULL
)	NULL
has	NULL
been	NULL
replaced	NULL
with	NULL
CFTR	NULL
cDNA	NULL
flanked	NULL
by	NULL
the	NULL
phosphoglycerate	NULL
kinase	NULL
promoter	NULL
and	NULL
a	NULL
bovine	NULL
growth	NULL
hormone	NULL
polyadenylation	NULL
site	NULL
.	NULL

The	NULL
E3	NULL
region	NULL
is	NULL
conserved	NULL
,	NULL
while	NULL
the	NULL
E4	NULL
region	NULL
is	NULL
modified	NULL
by	NULL
removal	NULL
of	NULL
all	NULL
open	NULL
reading	NULL
frames	NULL
(	NULL
between	NULL
nucleotides	NULL
32815	NULL
and	NULL
35577	NULL
)	NULL
and	NULL
replacement	NULL
with	NULL
the	NULL
E4	NULL
open	NULL
reading	NULL
frame	NULL
6	NULL
(	NULL
nucleotides	NULL
33178	NULL
to	NULL
34082	NULL
)	NULL
.	NULL

Ad2/CFTR-7	NULL
is	NULL
a	NULL
similar	NULL
construct	NULL
,	NULL
in	NULL
which	NULL
the	NULL
entire	NULL
E1	NULL
region	NULL
including	NULL
the	NULL
protein	NULL
IX	NULL
gene	NULL
(	NULL
nucleotides	NULL
546	NULL
to	NULL
4020	NULL
)	NULL
was	NULL
replaced	NULL
with	NULL
an	NULL
expression	NULL
cassette	NULL
encoding	NULL
the	NULL
ElA	NULL
promoter	NULL
,	NULL
CFTR	NULL
cDNA	NULL
,	NULL
and	NULL
the	NULL
early	NULL
polyadenylation	NULL
site	NULL
from	NULL
SV40	NULL
.	NULL

Ad2/	NULL
CFTR-7	NULL
contains	NULL
the	NULL
same	NULL
E4	NULL
modification	NULL
as	NULL
Ad2/CFTR-2	NULL
,	NULL
with	NULL
an	NULL
additional	NULL
deletion	NULL
in	NULL
the	NULL
E3	NULL
region	NULL
(	NULL
nucleotides	NULL
29293	NULL
to	NULL
30840	NULL
;	NULL
gp19K	NULL
retained	NULL
)	NULL
.	NULL

Since	NULL
Ad5	NULL
and	NULL
Ad2	NULL
are	NULL
99	NULL
to	NULL
100	NULL
%	NULL
identical	NULL
at	NULL
the	NULL
nucleotide	NULL
level	NULL
and	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
completely	NULL
cross-reactive	NULL
for	NULL
CTL	NULL
,	NULL
d/801	NULL
,	NULL
d/309	NULL
,	NULL
Ad5	NULL
,	NULL
and	NULL
Ad2	NULL
were	NULL
used	NULL
interchangeably	NULL
as	NULL
positive	NULL
controls	NULL
for	NULL
lysis	NULL
(	NULL
23	NULL
,	NULL
29	NULL
)	NULL
.	NULL

Mouse	NULL
infections	NULL
.	NULL

Six-	NULL
to	NULL
cight-week-old	NULL
male	NULL
C57BL/10SnJ	NULL
,	NULL
BALB/cByJ	NULL
,	NULL
and	NULL
C3HeB/FeJ	NULL
mice	NULL
(	NULL
Jackson	NULL
Laboratories	NULL
,	NULL
Bar	NULL
Harbor	NULL
,	NULL
Maine	NULL
)	NULL
were	NULL
inoculated	NULL
intraperitoncally	NULL
(	NULL
ip	NULL
.	NULL
)	NULL

with	NULL
2	NULL
X	NULL
10	NULL
``	NULL
PFU	NULL
of	NULL
Ad5	NULL
.	NULL

For	NULL
intranasal	NULL
(	NULL
i.n	NULL
.	NULL
)	NULL

inoculations	NULL
,	NULL
mice	NULL
were	NULL
anesthetized	NULL
with	NULL
Avertin	NULL
(	NULL
2,2,2-tribromoethanol	NULL
)	NULL
(	NULL
Aldrich	NULL
Chemical	NULL
Co.	NULL
,	NULL
Milwaukee	NULL
,	NULL
Wis.	NULL
)	NULL
,	NULL
and	NULL
25	NULL
pil	NULL
of	NULL
10	NULL
PFU	NULL
of	NULL
CsCl-banded	NULL
virus	NULL
per	NULL
ml	NULL
was	NULL
instilled	NULL
i.n	NULL
.	NULL

(	NULL
31	NULL
)	NULL
.	NULL

For	NULL
double	NULL
immunizations	NULL
,	NULL
a	NULL
second	NULL
administration	NULL
was	NULL
given	NULL
7	NULL
days	NULL
following	NULL
the	NULL
first	NULL
inoculation	NULL
.	NULL

Spleens	NULL
were	NULL
harvested	NULL
7	NULL
or	NULL
more	NULL
days	NULL
following	NULL
the	NULL
final	NULL
inoculation	NULL
.	NULL

CTL	NULL
assays	NULL
.	NULL

The	NULL
spleens	NULL
from	NULL
i.n	NULL
.	NULL

or	NULL
i.p	NULL
.	NULL

inoculated	NULL
mice	NULL
were	NULL
removed	NULL
,	NULL
stimulated	NULL
in	NULL
vitro	NULL
for	NULL
6	NULL
days	NULL
with	NULL
syngeneic	NULL
,	NULL
Ad-infected	NULL
y-irradiated	NULL
stimula-tors	NULL
,	NULL
and	NULL
assayed	NULL
against	NULL
*'Cr-labelled	NULL
targets	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
27	NULL
,	NULL
29	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
for	NULL
DÂ®-restricted	NULL
CTL	NULL
,	NULL
splenocytes	NULL
were	NULL
stimulated	NULL
in	NULL
vitro	NULL
with	NULL
SVB6KHA	NULL
(	NULL
KÂ°D	NULL
``	NULL
)	NULL
fibroblasts	NULL
infected	NULL
with	NULL
1754	NULL
or	NULL
dI801	NULL
and	NULL
assayed	NULL
against	NULL
virally	NULL
infected	NULL
SV2R	NULL
targets	NULL
(	NULL
K*	NULL
1D	NULL
``	NULL
)	NULL
or	NULL
the	NULL
E1A	NULL
transfectant	NULL
,	NULL
L13-14	NULL
,	NULL
which	NULL
has	NULL
been	NULL
described	NULL
elsewhere	NULL
(	NULL
27	NULL
)	NULL
.	NULL

SV2R	NULL
was	NULL
chosen	NULL
as	NULL
the	NULL
target	NULL
cell	NULL
because	NULL
E3	NULL
gp19K	NULL
does	NULL
not	NULL
suppress	NULL
CTL	NULL
recognition	NULL
in	NULL
this	NULL
cell	NULL
line	NULL
(	NULL
262	NULL
)	NULL
.	NULL

For	NULL
K*-restricted	NULL
CTL	NULL
,	NULL
splenocytes	NULL
were	NULL
restimulated	NULL
in	NULL
vitro	NULL
with	NULL
PSC3H	NULL
(	NULL
K*	NULL
1D	NULL
``	NULL
)	NULL
fibroblasts	NULL
infected	NULL
with	NULL
either	NULL
d/754	NULL
or	NULL
dI801	NULL
and	NULL
were	NULL
assayed	NULL
against	NULL
PSC3H	NULL
targets	NULL
.	NULL

For	NULL
K	NULL
``	NULL
and	NULL
D	NULL
``	NULL
CTL	NULL
expansion	NULL
,	NULL
BALB/c	NULL
spleen	NULL
cells	NULL
were	NULL
restimulated	NULL
with	NULL
SVBALB	NULL
(	NULL
K	NULL
``	NULL
D	NULL
``	NULL
)	NULL
fibroblasts	NULL
infected	NULL
with	NULL
41754	NULL
or	NULL
df801	NULL
and	NULL
assayed	NULL
against	NULL
SVHTI	NULL
(	NULL
K	NULL
``	NULL
D	NULL
``	NULL
)	NULL
or	NULL
SVHTG	NULL
(	NULL
K	NULL
``	NULL
D	NULL
``	NULL
)	NULL
targets	NULL
treated	NULL
with	NULL
50	NULL
U	NULL
of	NULL
gamma	NULL
interferon	NULL
(	NULL
IFN-y	NULL
)	NULL
(	NULL
Genzyme	NULL
Corp.	NULL
,	NULL
Framingham	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

for	NULL
24	NULL
h	NULL
to	NULL
overcome	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
Ad	NULL
E3	NULL
gp19K	NULL
.	NULL

When	NULL
viruses	NULL
that	NULL
lacked	NULL
E1A	NULL
were	NULL
used	NULL
,	NULL
targets	NULL
were	NULL
infected	NULL
with	NULL
1,000	NULL
PFU	NULL
per	NULL
cell	NULL
2	NULL
days	NULL
prior	NULL
to	NULL
assaying	NULL
,	NULL
while	NULL
all	NULL
other	NULL
targets	NULL
were	NULL
infected	NULL
with	NULL
100	NULL
PFU	NULL
per	NULL
cell	NULL
the	NULL
day	NULL
before	NULL
assaying	NULL
.	NULL

All	NULL
targets	NULL
were	NULL
labelled	NULL
J.	NULL
ViRoL	NULL
.	NULL

with	NULL
200	NULL
p.Ci	NULL
of	NULL
NaZ	NULL
'	NULL
CrO	NULL
,	NULL
(	NULL
New	NULL
England	NULL
Nuclear	NULL
,	NULL
Boston	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

on	NULL
the	NULL
day	NULL
prior	NULL
to	NULL
assaying	NULL
.	NULL

CTL	NULL
activity	NULL
was	NULL
measured	NULL
by	NULL
a	NULL
5-h	NULL
Â°*Cr	NULL
release	NULL
assay	NULL
.	NULL

Results	NULL
were	NULL
calculated	NULL
from	NULL
the	NULL
mean	NULL
of	NULL
triplicate	NULL
samples	NULL
and	NULL
expressed	NULL
as	NULL
(	NULL
E	NULL
C	NULL
)	NULL
/	NULL
(	NULL
M	NULL
-	NULL
C	NULL
)	NULL
x	NULL
100	NULL
=	NULL
percent	NULL
specific	NULL
lysis	NULL
,	NULL
where	NULL
C	NULL
equals	NULL
counts	NULL
per	NULL
minute	NULL
released	NULL
by	NULL
nonstimulated	NULL
lymphocytes	NULL
,	NULL
Â£	NULL
equals	NULL
counts	NULL
per	NULL
minute	NULL
released	NULL
by	NULL
sensitized	NULL
lymphocytes	NULL
,	NULL
and	NULL
M	NULL
equals	NULL
maximum	NULL
releasable	NULL
counts	NULL
per	NULL
minute	NULL
,	NULL
determined	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
0.05	NULL
ml	NULL
of	NULL
1	NULL
N	NULL
HCI	NULL
to	NULL
0.05	NULL
ml	NULL
of	NULL
target	NULL
cells	NULL
.	NULL

Data	NULL
are	NULL
percent	NULL
specific	NULL
lysis	NULL
+	NULL
standard	NULL
errors	NULL
of	NULL
the	NULL
means	NULL
.	NULL

The	NULL
graphs	NULL
presented	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
to	NULL
five	NULL
experiments	NULL
with	NULL
at	NULL
least	NULL
two	NULL
mice	NULL
per	NULL
group	NULL
in	NULL
each	NULL
.	NULL

Detection	NULL
of	NULL
infectivity	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
the	NULL
target	NULL
cells	NULL
were	NULL
infected	NULL
,	NULL
5	NULL
x	NULL
10Â°	NULL
target	NULL
cells	NULL
were	NULL
allowed	NULL
to	NULL
adhere	NULL
to	NULL
a	NULL
multispot	NULL
microscope	NULL
slide	NULL
(	NULL
Shandon	NULL
,	NULL
Pittsburgh	NULL
,	NULL
Pa.	NULL
)	NULL
for	NULL
5	NULL
h.	NULL
The	NULL
cells	NULL
were	NULL
then	NULL
fixed	NULL
in	NULL
methanol	NULL
(	NULL
-20Â°C	NULL
)	NULL
for	NULL
10	NULL
min	NULL
and	NULL
treated	NULL
with	NULL
the	NULL
DAKO	NULL
LSAB	NULL
(	NULL
R	NULL
)	NULL
II	NULL
kit	NULL
(	NULL
DAKO	NULL
Corp.	NULL
,	NULL
Carpinteria	NULL
,	NULL
Calif.	NULL
)	NULL
by	NULL
using	NULL
a	NULL
rabbit	NULL
anti-72K	NULL
(	NULL
DNA	NULL
binding	NULL
protein	NULL
)	NULL
serum	NULL
(	NULL
a	NULL
gift	NULL
of	NULL
Daniel	NULL
F.	NULL
Kessling	NULL
)	NULL
as	NULL
the	NULL
primary	NULL
antibody	NULL
.	NULL

Briefly	NULL
,	NULL
endogenous	NULL
peroxidase	NULL
was	NULL
neutralized	NULL
with	NULL
3	NULL
%	NULL
H	NULL
,	NULL
O	NULL
,	NULL
for	NULL
5	NULL
min	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
incubated	NULL
with	NULL
the	NULL
anti-72K	NULL
serum	NULL
(	NULL
1:500	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
[	NULL
PBS	NULL
]	NULL
plus	NULL
1	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
)	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
(	NULL
RT	NULL
)	NULL
.	NULL

The	NULL
slides	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
PBS	NULL
and	NULL
incubated	NULL
with	NULL
biotinylated	NULL
anti-rabbit	NULL
antibody	NULL
for	NULL
30	NULL
min	NULL
at	NULL
RT	NULL
.	NULL

The	NULL
slides	NULL
were	NULL
again	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
PBS	NULL
and	NULL
subsequently	NULL
incubated	NULL
with	NULL
streptavidin	NULL
peroxidase	NULL
for	NULL
30	NULL
min	NULL
at	NULL
RT	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
five	NULL
times	NULL
with	NULL
PBS	NULL
and	NULL
incubated	NULL
with	NULL
3	NULL
%	NULL
3-amino-9-ethylcarbazole	NULL
for	NULL
10	NULL
min	NULL
at	NULL
RT	NULL
.	NULL

The	NULL
slides	NULL
were	NULL
washed	NULL
in	NULL
H0	NULL
,	NULL
covered	NULL
in	NULL
90	NULL
%	NULL
glycerol	NULL
,	NULL
and	NULL
examined	NULL
under	NULL
a	NULL
light	NULL
microscope	NULL
for	NULL
infectivity	NULL
.	NULL

In	NULL
the	NULL
experiments	NULL
described	NULL
here	NULL
,	NULL
greater	NULL
than	NULL
85	NULL
%	NULL
of	NULL
the	NULL
target	NULL
cells	NULL
were	NULL
infected	NULL
.	NULL

RESULTS	NULL
Multiple	NULL
inoculations	NULL
lead	NULL
to	NULL
the	NULL
recognition	NULL
of	NULL
immunorecessive	NULL
epitope	NULL
(	NULL
s	NULL
)	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
E1A	NULL
is	NULL
the	NULL
immunodominant	NULL
antigen	NULL
in	NULL
the	NULL
C57BL10/SnJ	NULL
(	NULL
B10	NULL
)	NULL
strain	NULL
,	NULL
B10	NULL
mice	NULL
were	NULL
inoculated	NULL
i.p	NULL
.	NULL

with	NULL
Ad5	NULL
and	NULL
assayed	NULL
against	NULL
targets	NULL
that	NULL
lacked	NULL
only	NULL
the	NULL
E1A	NULL
region	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

These	NULL
Ad-specific	NULL
CTL	NULL
recognized	NULL
the	NULL
E1A	NULL
transfectant	NULL
(	NULL
L13-14	NULL
)	NULL
and	NULL
were	NULL
unable	NULL
to	NULL
lyse	NULL
the	NULL
di312	NULL
(	NULL
AE1A	NULL
)	NULL
-infected	NULL
target	NULL
which	NULL
lacked	NULL
E1A	NULL
.	NULL

These	NULL
results	NULL
corroborate	NULL
the	NULL
findings	NULL
of	NULL
Rawle	NULL
et	NULL
al	NULL
.	NULL

(	NULL
27	NULL
)	NULL
that	NULL
the	NULL
immunodominant	NULL
epitope	NULL
in	NULL
B10	NULL
mice	NULL
is	NULL
E1A	NULL
and	NULL
that	NULL
this	NULL
response	NULL
is	NULL
D	NULL
``	NULL
restricted	NULL
.	NULL

Since	NULL
gene	NULL
therapy	NULL
applications	NULL
will	NULL
likely	NULL
require	NULL
multiple	NULL
administrations	NULL
of	NULL
Ad	NULL
vectors	NULL
,	NULL
B10	NULL
mice	NULL
were	NULL
immunized	NULL
twice	NULL
ip	NULL
.	NULL

with	NULL
wild-type	NULL
Ad2	NULL
,	NULL
and	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
Ad	NULL
immune	NULL
response	NULL
was	NULL
analyzed	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
single	NULL
immunization	NULL
,	NULL
CTL	NULL
were	NULL
now	NULL
capable	NULL
of	NULL
lysing	NULL
not	NULL
only	NULL
the	NULL
E1A	NULL
transfectant	NULL
(	NULL
L13-14	NULL
)	NULL
but	NULL
also	NULL
targets	NULL
that	NULL
did	NULL
not	NULL
express	NULL
either	NULL
E1A	NULL
or	NULL
E1B	NULL
,	NULL
albeit	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
Ad2/CFTR-2	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
upon	NULL
multiple	NULL
immunizations	NULL
,	NULL
not	NULL
only	NULL
is	NULL
the	NULL
immunodominant	NULL
CTL	NULL
population	NULL
expanded	NULL
,	NULL
but	NULL
a	NULL
subpopulation	NULL
of	NULL
CTL	NULL
that	NULL
recognizes	NULL
antigen	NULL
(	NULL
s	NULL
)	NULL
that	NULL
lies	NULL
outside	NULL
E1	NULL
(	NULL
E1A	NULL
and	NULL
E1B	NULL
)	NULL
is	NULL
activated	NULL
.	NULL

A	NULL
possible	NULL
solution	NULL
for	NULL
circumventing	NULL
CTL	NULL
clearance	NULL
of	NULL
gene	NULL
therapy	NULL
vectors	NULL
and	NULL
prolonging	NULL
transgene	NULL
expression	NULL
is	NULL
the	NULL
elimination	NULL
of	NULL
the	NULL
immunodominant	NULL
antigen	NULL
from	NULL
the	NULL
vector	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
eliminating	NULL
the	NULL
immunodominant	NULL
antigen	NULL
(	NULL
E1A	NULL
)	NULL
would	NULL
affect	NULL
the	NULL
generation	NULL
of	NULL
Ad-specific	NULL
CTL	NULL
,	NULL
B10	NULL
mice	NULL
were	NULL
inoculated	NULL
once	NULL
or	NULL
twice	NULL
i.p	NULL
.	NULL

with	NULL
either	NULL
41312	NULL
(	NULL
AE1A	NULL
)	NULL
or	NULL
Ad2/CFTR-2	NULL
(	NULL
AE1A	NULL
and	NULL
E1B	NULL
)	NULL
.	NULL

Following	NULL
a	NULL
single	NULL
inoculation	NULL
with	NULL
@	NULL
/312	NULL
,	NULL
no	NULL
Ad-specific	NULL
CTL	NULL
were	NULL
generated	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
immunodominant	NULL
antigen	NULL
,	NULL
multiple	NULL
immunizations	NULL
generated	NULL
an	NULL
Ad-specific	NULL
CTL	NULL
response	NULL
that	NULL
was	NULL
directed	NULL
against	NULL
an	NULL
epitope	NULL
in	NULL
a	NULL
region	NULL
outside	NULL
E1	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
the	NULL
CTL	NULL
response	NULL
in	NULL
B10	NULL
mice	NULL
(	NULL
H-2	NULL
``	NULL
)	NULL
after	NULL
a	NULL
single	NULL
immunization	NULL
with	NULL
wild-type	NULL
Ad	NULL
was	NULL
focused	NULL
on	NULL
a	NULL
single	NULL
immunodominant	NULL
antigen	NULL
,	NULL
E1A	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
multiple	NULL
immunizations	NULL
with	NULL
viruses	NULL
with	NULL
or	NULL
without	NULL
the	NULL
immunodominant	NULL
antigen	NULL
generated	NULL
a	NULL
CTL	NULL
response	NULL
against	NULL
immunorecessive	NULL
or	NULL
subdominant	NULL
antigens	NULL
.	NULL

Multiple-i.n	NULL
.	NULL

inoculations	NULL
generate	NULL
the	NULL
same	NULL
Ad-specific	NULL
immune	NULL
response	NULL
as	NULL
i.p	NULL
.	NULL

inoculations	NULL
.	NULL

Since	NULL
the	NULL
treatment	NULL
of	NULL
cystic	NULL
fibrosis	NULL
will	NULL
likely	NULL
require	NULL
multiple	NULL
administrations	NULL
to	NULL
the	NULL
lung	NULL
,	NULL
the	NULL
CTL	NULL
response	NULL
was	NULL
evaluated	NULL
after	NULL
double	NULL
i.n	NULL
.	NULL

immu-	NULL
Vor	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
100	NULL
80	NULL
7	NULL
Â®	NULL
&	NULL
Â»	NULL
0	NULL
sod	NULL
o	NULL
i	NULL
a	NULL
4	NULL
wi	NULL
A.	NULL
a	NULL
z	NULL
20	NULL
4	NULL
0	NULL
4	NULL
M	NULL
20	NULL
60:1	NULL
20:1	NULL
6:1	NULL
E	NULL
:	NULL
T	NULL
RATIO	NULL
100	NULL
B	NULL
80	NULL
4	NULL
@	NULL
Â®	NULL
2p	NULL
605	NULL
-B-	NULL
-	NULL
d1309	NULL
(	NULL
ETA+E1B4	NULL
)	NULL
o	NULL
--	NULL
-	NULL
di312	NULL
(	NULL
E1A-E1B+	NULL
)	NULL
)	NULL
g	NULL
+	NULL
-O-	NULL
_	NULL
Ad	NULL
2CFTR-2	NULL
E1B-	NULL
)	NULL
i	NULL
-	NULL
@	NULL
-	NULL
-	NULL
Lis14	NULL
(	NULL
EAs	NULL
)	NULL
a	NULL
:	NULL
P	NULL
-C-	NULL
UNINFEcTED	NULL
o	NULL
{	NULL
=	NULL
8	NULL
--	NULL
--	NULL
g_	NULL
--	NULL
--	NULL
o	NULL
--	NULL
-HÂ§	NULL
~20	NULL
u	NULL
t	NULL
t	NULL
-r	NULL
60:1	NULL
20:1	NULL
611	NULL
2:1	NULL
E	NULL
:	NULL
T	NULL
RATiO	NULL
100	NULL
C	NULL
80	NULL
4	NULL
P4	NULL
Â®	NULL
Â»	NULL
o	NULL
694	NULL
0	NULL
rs	NULL
0	NULL
40	NULL
4	NULL
PU	NULL
c.	NULL
Â®	NULL
ae	NULL
20	NULL
7	NULL
o-+20	NULL
t	NULL
t	NULL
t	NULL
u	NULL
60:1	NULL
20:1	NULL
6:1	NULL
2:1	NULL
E	NULL
:	NULL
T	NULL
RATIO	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

The	NULL
Ad	NULL
CTL	NULL
response	NULL
in	NULL
C57BL10/SnJ	NULL
mice	NULL
following	NULL
i.p	NULL
.	NULL

injection	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
CTL	NULL
response	NULL
after	NULL
one	NULL
injection	NULL
of	NULL
Ad5	NULL
i.p	NULL
.	NULL

;	NULL
(	NULL
B	NULL
)	NULL
CTL	NULL
response	NULL
after	NULL
two	NULL
injections	NULL
of	NULL
Ad2	NULL
i.p	NULL
.	NULL

;	NULL
(	NULL
C	NULL
)	NULL
CTL	NULL
response	NULL
after	NULL
two	NULL
i.p	NULL
.	NULL

injections	NULL
of	NULL
Ad2/	NULL
CFTR-2	NULL
.	NULL

E	NULL
:	NULL
T	NULL
ratio	NULL
,	NULL
effector-to-target-cell	NULL
ratio	NULL
.	NULL

nizations	NULL
.	NULL

B10	NULL
mice	NULL
were	NULL
inoculated	NULL
twice	NULL
i.n	NULL
.	NULL

with	NULL
wild-type	NULL
Ad	NULL
?	NULL

and	NULL
assayed	NULL
against	NULL
targets	NULL
that	NULL
express	NULL
the	NULL
immunodominant	NULL
E1A	NULL
antigen	NULL
(	NULL
d/801	NULL
)	NULL
or	NULL
lack	NULL
E1A/E1B	NULL
expression	NULL
(	NULL
Ad2/	NULL
CFTR-2	NULL
)	NULL
.	NULL

As	NULL
was	NULL
observed	NULL
following	NULL
multiple	NULL
i.p	NULL
.	NULL

inoculations	NULL
with	NULL
wild-type	NULL
Ad	NULL
,	NULL
the	NULL
CTL	NULL
response	NULL
was	NULL
directed	NULL
against	NULL
E1A	NULL
(	NULL
L13-14	NULL
)	NULL
and	NULL
toward	NULL
an	NULL
epitope	NULL
outside	NULL
E1	NULL
(	NULL
Ad2/CFTR-2	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

When	NULL
B10	NULL
mice	NULL
were	NULL
immunized	NULL
twice	NULL
i.n	NULL
.	NULL

with	NULL
Ad2/CFTR-2	NULL
,	NULL
which	NULL
lacks	NULL
E1	NULL
,	NULL
only	NULL
the	NULL
non-El	NULL
epitope	NULL
was	NULL
recognized	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
the	NULL
E1A	NULL
transfectant	NULL
L13-14	NULL
was	NULL
not	NULL
lysed	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

The	NULL
lysis	NULL
of	NULL
targets	NULL
infected	NULL
with	NULL
Ad2/CFTR-2	NULL
(	NULL
AE1A	NULL
and	NULL
E1B	NULL
)	NULL
indicated	NULL
that	NULL
at	NULL
least	NULL
one	NULL
of	NULL
the	NULL
immunorecessive	NULL
epitopes	NULL
was	NULL
outside	NULL
of	NULL
the	NULL
E1	NULL
region	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
in	NULL
B10	NULL
mice	NULL
,	NULL
multiple	NULL
immunizations	NULL
either	NULL
i.p	NULL
.	NULL

or	NULL
in	NULL
.	NULL

with	NULL
wild-type	NULL
or	NULL
recombinant	NULL
Ad	NULL
leads	NULL
to	NULL
the	NULL
generation	NULL
of	NULL
CTL	NULL
that	NULL
recognize	NULL
immunorecessive	NULL
epitopes	NULL
even	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
immunodominant	NULL
epitope	NULL
.	NULL

K*-restricted	NULL
CTL	NULL
from	NULL
C3HeB/FeJ	NULL
mice	NULL
recognize	NULL
E1B	NULL
as	NULL
the	NULL
immunodominant	NULL
antigen	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
previously	NULL
that	NULL
CTL	NULL
from	NULL
C3H	NULL
mice	NULL
are	NULL
K*-restricted	NULL
and	NULL
do	NULL
not	NULL
recognize	NULL
CTL	NULL
FROM	NULL
Ad	NULL
IMMUNIZATIONS	NULL
RECOGNIZE	NULL
EPITOPES	NULL
-	NULL
2279	NULL
E1A	NULL
;	NULL
however	NULL
,	NULL
the	NULL
immunodominant	NULL
antigen	NULL
was	NULL
not	NULL
defined	NULL
(	NULL
27	NULL
)	NULL
.	NULL

To	NULL
map	NULL
the	NULL
immunodominant	NULL
antigen	NULL
,	NULL
C3H	NULL
mice	NULL
were	NULL
inoculated	NULL
once	NULL
i.p	NULL
.	NULL

with	NULL
Ad5	NULL
and	NULL
assayed	NULL
against	NULL
targets	NULL
that	NULL
lack	NULL
the	NULL
E1	NULL
region	NULL
.	NULL

CTL	NULL
generated	NULL
from	NULL
Ad	NULL
immunizations	NULL
were	NULL
unable	NULL
to	NULL
lyse	NULL
the	NULL
Ad2/CFTR-2	NULL
(	NULL
AE1A	NULL
and	NULL
E1B	NULL
)	NULL
or	NULL
Ad2	NULL
?	NULL

/CFTR-7	NULL
(	NULL
AE1A	NULL
and	NULL
E1B	NULL
)	NULL
-infected	NULL
targets	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

Since	NULL
K*-restricted	NULL
effectors	NULL
do	NULL
not	NULL
recognize	NULL
E1A	NULL
,	NULL
our	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
Ad-specific	NULL
CTL	NULL
are	NULL
directed	NULL
against	NULL
epitope	NULL
(	NULL
s	NULL
)	NULL
in	NULL
E1B	NULL
.	NULL

To	NULL
verify	NULL
this	NULL
hypothesis	NULL
,	NULL
K*-restricted	NULL
CTL	NULL
were	NULL
assayed	NULL
against	NULL
targets	NULL
lacking	NULL
either	NULL
E1A	NULL
(	NULL
d/312	NULL
)	NULL
or	NULL
E1B	NULL
(	NULL
d1313	NULL
)	NULL
only	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrated	NULL
that	NULL
K*-restricted	NULL
CTL	NULL
are	NULL
capable	NULL
of	NULL
lysing	NULL
targets	NULL
that	NULL
contained	NULL
the	NULL
E1B	NULL
region	NULL
(	NULL
41309	NULL
and	NULL
d/312	NULL
)	NULL
,	NULL
but	NULL
not	NULL
targets	NULL
deleted	NULL
in	NULL
E1B	NULL
(	NULL
Ad2/CFTR-2	NULL
,	NULL
Ad2/CFTR-7	NULL
,	NULL
and	NULL
d/313	NULL
)	NULL
,	NULL
confirming	NULL
that	NULL
E1B	NULL
contains	NULL
the	NULL
immunodominant	NULL
K*-restricted	NULL
epitope	NULL
.	NULL

Immunorecessive	NULL
epitopes	NULL
are	NULL
not	NULL
recognized	NULL
after	NULL
immunizations	NULL
with	NULL
vectors	NULL
that	NULL
lack	NULL
the	NULL
immunodominant	NULL
K*	NULL
epitope	NULL
.	NULL

With	NULL
the	NULL
knowledge	NULL
that	NULL
the	NULL
immunodominant	NULL
K*	NULL
epitope	NULL
lies	NULL
within	NULL
the	NULL
E1B	NULL
region	NULL
,	NULL
the	NULL
question	NULL
of	NULL
multiple	NULL
immunizations	NULL
and	NULL
the	NULL
redirection	NULL
of	NULL
the	NULL
CTL	NULL
response	NULL
toward	NULL
immunorecessive	NULL
epitopes	NULL
was	NULL
investigated	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
CTL	NULL
generated	NULL
from	NULL
multiple	NULL
immunizations	NULL
recognize	NULL
immunorecessive	NULL
epitopes	NULL
as	NULL
had	NULL
occurred	NULL
in	NULL
B10	NULL
mice	NULL
,	NULL
C3H	NULL
mice	NULL
were	NULL
inoculated	NULL
twice	NULL
i.p	NULL
.	NULL

or	NULL
i.n	NULL
.	NULL

with	NULL
wild-type	NULL
Ad2	NULL
or	NULL
Ad2/CFTR-2	NULL
(	NULL
AE1A	NULL
and	NULL
E1B	NULL
)	NULL
.	NULL

CTL	NULL
from	NULL
both	NULL
i.p	NULL
.	NULL

(	NULL
Fig	NULL
.	NULL

5A	NULL
and	NULL
B	NULL
)	NULL
and	NULL
i.n	NULL
.	NULL

(	NULL
Fig	NULL
.	NULL

6A	NULL
and	NULL
B	NULL
)	NULL
inoculations	NULL
failed	NULL
to	NULL
recognize	NULL
immunorecessive	NULL
epitopes	NULL
.	NULL

Even	NULL
after	NULL
multiple	NULL
immunizations	NULL
,	NULL
effectors	NULL
against	NULL
wild-type	NULL
Ad	NULL
responded	NULL
only	NULL
to	NULL
the	NULL
E1B	NULL
an	NULL
80	NULL
60	NULL
4	NULL
E4	NULL
8	NULL
.	NULL

2	NULL
ao	NULL
{	NULL
0	NULL
3	NULL
4	NULL
&	NULL
.	NULL

20	NULL
4	NULL
w	NULL
at	NULL
0	NULL
7	NULL
Wu	NULL
20	NULL
t	NULL
r	NULL
u	NULL
60:1	NULL
20:1	NULL
6:1	NULL
E	NULL
:	NULL
T	NULL
Ratio	NULL
-	NULL
Ad2	NULL
(	NULL
E1A+E1B4	NULL
)	NULL
-A-	NULL
-	NULL
dl801	NULL
(	NULL
E1A+E1B+	NULL
)	NULL
-O-	NULL
_	NULL
Ad	NULL
2CFTR-2	NULL
(	NULL
E1A~	NULL
,	NULL
E1B-	NULL
)	NULL
-	NULL
@	NULL
-	NULL
L134	NULL
-C-	NULL
_	NULL
UNINFECTED	NULL
so	NULL
B	NULL
60	NULL
4	NULL
&	NULL
$	NULL
2	NULL
a0	NULL
{	NULL
0	NULL
E=	NULL
8	NULL
o	NULL
.	NULL

20	NULL
4	NULL
a	NULL
l	NULL
o	NULL
{	NULL
E	NULL
k	NULL
Q	NULL
+20	NULL
t	NULL
u	NULL
t	NULL
60:1	NULL
20:1	NULL
6:1	NULL
E	NULL
:	NULL
T	NULL
Ratio	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

The	NULL
Ad	NULL
CTL	NULL
response	NULL
in	NULL
C57BL10/SnJ	NULL
mice	NULL
after	NULL
i.n	NULL
.	NULL

inoculations	NULL
.	NULL

(	NULL
A	NULL
)	NULL
CTL	NULL
from	NULL
mice	NULL
immunized	NULL
twice	NULL
i.n	NULL
.	NULL

with	NULL
Ad2	NULL
;	NULL
(	NULL
B	NULL
)	NULL
CTL	NULL
response	NULL
from	NULL
mice	NULL
immunized	NULL
twice	NULL
i.n	NULL
.	NULL

with	NULL
Ad2/CFTR-2	NULL
.	NULL

E	NULL
:	NULL
T	NULL
ratio	NULL
,	NULL
effector-to-target-cell	NULL
ratio	NULL
.	NULL

2280	NULL
SPARER	NULL
ET	NULL
AL	NULL
.	NULL

80	NULL
A	NULL
-A-	NULL
-	NULL
d1801	NULL
(	NULL
E1A+E184	NULL
)	NULL
-O-	NULL
_	NULL
Ad	NULL
2CFTR-2	NULL
(	NULL
E1A~	NULL
,	NULL
E1B-	NULL
)	NULL
-	NULL
Ad	NULL
2CFTRT	NULL
E1B-	NULL
)	NULL
60	NULL
4	NULL
-L-	NULL
UNINFECTED	NULL
F	NULL
40	NULL
7	NULL
4	NULL
9	NULL
m	NULL
x	NULL
nl	NULL
o	NULL
20	NULL
1	NULL
A	NULL
Â®	NULL
&	NULL
o	NULL
{	NULL
-20	NULL
T	NULL
T	NULL
t	NULL
20:1	NULL
6:1	NULL
2:1	NULL
E	NULL
:	NULL
T	NULL
RATIO	NULL
so	NULL
B	NULL
-I-	NULL
-	NULL
d1309	NULL
(	NULL
E1A+	NULL
,	NULL
E1B4	NULL
)	NULL
-ik-	NULL
-	NULL
di312	NULL
(	NULL
E1A-	NULL
,	NULL
E1B+	NULL
)	NULL
--	NULL
@	NULL
--	NULL
-	NULL
d1313	NULL
(	NULL
E1A+	NULL
,	NULL
Â£18	NULL
)	NULL
60	NULL
-	NULL
-L-	NULL
_	NULL
UNINFECTED	NULL
w	NULL
Â®	NULL
40	NULL
{	NULL
4	NULL
o	NULL
Ie	NULL
E	NULL
8	NULL
20	NULL
{	NULL
i	NULL
&	NULL
o	NULL
-20	NULL
r	NULL
t	NULL
t	NULL
20:1	NULL
6:1	NULL
2:1	NULL
E	NULL
:	NULL
T	NULL
RATIO	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Large	NULL
deletion	NULL
mapping	NULL
of	NULL
the	NULL
antigen	NULL
recognized	NULL
by	NULL
CTL	NULL
from	NULL
C3H	NULL
mice	NULL
inoculated	NULL
once	NULL
i.p	NULL
.	NULL

with	NULL
Ad5	NULL
.	NULL

(	NULL
A	NULL
)	NULL
CTL	NULL
from	NULL
C3H	NULL
(	NULL
Z-2K*	NULL
)	NULL
mice	NULL
assayed	NULL
against	NULL
Ad2	NULL
E1A/E1B	NULL
deletion	NULL
mutants	NULL
;	NULL
(	NULL
B	NULL
)	NULL
mapping	NULL
of	NULL
the	NULL
K*-restricted	NULL
CTL	NULL
antigen	NULL
with	NULL
Ad5	NULL
E1A	NULL
or	NULL
E1B	NULL
deletion	NULL
mutants	NULL
.	NULL

E	NULL
:	NULL
T	NULL
ratio	NULL
,	NULL
effector-to-target-cell	NULL
ratio	NULL
.	NULL

tigen	NULL
and	NULL
not	NULL
to	NULL
any	NULL
subdominant	NULL
epitope	NULL
(	NULL
s	NULL
)	NULL
in	NULL
Ad2/CFTR-2	NULL
or	NULL
Ad2/CFTR-7	NULL
targets	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
and	NULL
6A	NULL
)	NULL
.	NULL

When	NULL
Ad2/CFTR-2	NULL
was	NULL
the	NULL
inoculating	NULL
agent	NULL
,	NULL
there	NULL
was	NULL
little	NULL
or	NULL
no	NULL
Ad-specific	NULL
CTL	NULL
response	NULL
,	NULL
indicating	NULL
that	NULL
no	NULL
immunorecessive	NULL
epitopes	NULL
were	NULL
recognized	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
and	NULL
6B	NULL
)	NULL
.	NULL

Considering	NULL
that	NULL
the	NULL
in	NULL
vitro	NULL
stimulating	NULL
cell	NULL
could	NULL
be	NULL
altering	NULL
the	NULL
subdominant	NULL
response	NULL
,	NULL
wild-type	NULL
and	NULL
Ad2/CFTR-2-primed	NULL
splenocytes	NULL
were	NULL
restimulated	NULL
in	NULL
vitro	NULL
with	NULL
PSC3H	NULL
fibroblasts	NULL
infected	NULL
with	NULL
Ad2/	NULL
CFTR-2	NULL
(	NULL
AE1A	NULL
and	NULL
E1B	NULL
)	NULL
instead	NULL
of	NULL
4/801	NULL
.	NULL

In	NULL
neither	NULL
case	NULL
were	NULL
CTL	NULL
against	NULL
subdominant	NULL
epitopes	NULL
detected	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Only	NULL
after	NULL
inoculation	NULL
of	NULL
Ad2/CFTR-2	NULL
three	NULL
times	NULL
i.n	NULL
.	NULL

was	NULL
a	NULL
minimal	NULL
but	NULL
sporadic	NULL
Ad-specific	NULL
response	NULL
detected	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
phenomenon	NULL
observed	NULL
with	NULL
B10	NULL
mice	NULL
(	NULL
Â£7-2	NULL
``	NULL
)	NULL
,	NULL
C3H	NULL
mice	NULL
(	NULL
H-2	NULL
``	NULL
)	NULL
had	NULL
diminished	NULL
ability	NULL
to	NULL
recognize	NULL
subdominant	NULL
epitopes	NULL
even	NULL
after	NULL
multiple	NULL
immunizations	NULL
.	NULL

Treatment	NULL
of	NULL
BALB/c	NULL
target	NULL
cells	NULL
with	NULL
IFN-y	NULL
is	NULL
necessary	NULL
to	NULL
overcome	NULL
the	NULL
E3-gp19K	NULL
block	NULL
to	NULL
CTL	NULL
recognition	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
the	NULL
generation	NULL
of	NULL
immunorecessive	NULL
epitopes	NULL
is	NULL
generalizable	NULL
to	NULL
other	NULL
mouse	NULL
strains	NULL
,	NULL
multiple	NULL
immunization	NULL
protocols	NULL
were	NULL
applied	NULL
to	NULL
BALB/c	NULL
mice	NULL
.	NULL

Before	NULL
examination	NULL
of	NULL
the	NULL
subdominant	NULL
response	NULL
,	NULL
the	NULL
immunodominant	NULL
epitope	NULL
was	NULL
delineated	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
reported	NULL
that	NULL
the	NULL
immune	NULL
response	NULL
to	NULL
Ad	NULL
in	NULL
BALB/c	NULL
mice	NULL
is	NULL
both	NULL
KZ	NULL
and	NULL
DS	NULL
restricted	NULL
and	NULL
is	NULL
not	NULL
directed	NULL
against	NULL
E1A	NULL
(	NULL
27	NULL
)	NULL
.	NULL

To	NULL
map	NULL
the	NULL
epitope	NULL
(	NULL
s	NULL
)	NULL
recognized	NULL
in	NULL
BALB/c	NULL
mice	NULL
,	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
CTL	NULL
protocol	NULL
J.	NULL
ViRoL	NULL
.	NULL

was	NULL
needed	NULL
to	NULL
overcome	NULL
the	NULL
Ad	NULL
E3	NULL
gp19K	NULL
suppression	NULL
of	NULL
CTL	NULL
recognition	NULL
in	NULL
K	NULL
``	NULL
-expressing	NULL
targets	NULL
.	NULL

The	NULL
Ad	NULL
E3	NULL
gp19K	NULL
protein	NULL
is	NULL
capable	NULL
of	NULL
binding	NULL
and	NULL
retaining	NULL
the	NULL
MHC	NULL
class	NULL
I	NULL
molecules	NULL
of	NULL
particular	NULL
haplotypes	NULL
in	NULL
the	NULL
endoplasmic	NULL
reticulum	NULL
(	NULL
1	NULL
)	NULL
,	NULL
preventing	NULL
CTL	NULL
lysis	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Gp19K	NULL
binds	NULL
strongly	NULL
to	NULL
K	NULL
``	NULL
and	NULL
D	NULL
``	NULL
molecules	NULL
while	NULL
DC	NULL
and	NULL
K*	NULL
are	NULL
unaffected	NULL
by	NULL
gp19K	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Gp19K	NULL
did	NULL
not	NULL
present	NULL
an	NULL
obstacle	NULL
in	NULL
C3H	NULL
targets	NULL
because	NULL
gp19K	NULL
does	NULL
not	NULL
bind	NULL
to	NULL
the	NULL
K*	NULL
allele	NULL
.	NULL

In	NULL
the	NULL
B10	NULL
(	NULL
D	NULL
``	NULL
)	NULL
experiments	NULL
described	NULL
above	NULL
,	NULL
the	NULL
gp19K	NULL
effect	NULL
was	NULL
overcome	NULL
by	NULL
using	NULL
a	NULL
cell	NULL
line	NULL
in	NULL
which	NULL
gp19K	NULL
does	NULL
not	NULL
function	NULL
to	NULL
suppress	NULL
CTL	NULL
recognition	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Since	NULL
gp19K	NULL
binds	NULL
strongly	NULL
to	NULL
K	NULL
``	NULL
and	NULL
we	NULL
have	NULL
not	NULL
found	NULL
a	NULL
K	NULL
``	NULL
cell	NULL
line	NULL
in	NULL
which	NULL
gp19K	NULL
does	NULL
not	NULL
function	NULL
,	NULL
an	NULL
alternative	NULL
method	NULL
was	NULL
needed	NULL
to	NULL
overcome	NULL
the	NULL
gp19K	NULL
suppression	NULL
of	NULL
CTL	NULL
recognition	NULL
.	NULL

A	NULL
24-h	NULL
treatment	NULL
of	NULL
targets	NULL
with	NULL
IFN-y	NULL
,	NULL
which	NULL
upregulates	NULL
MHC	NULL
class	NULL
I	NULL
expression	NULL
,	NULL
was	NULL
previously	NULL
shown	NULL
to	NULL
overcome	NULL
the	NULL
strong	NULL
gp19K	NULL
block	NULL
in	NULL
D	NULL
``	NULL
cells	NULL
(	NULL
31	NULL
)	NULL
.	NULL

To	NULL
verify	NULL
that	NULL
this	NULL
treatment	NULL
would	NULL
overcome	NULL
the	NULL
gp19K	NULL
block	NULL
in	NULL
K	NULL
``	NULL
-expressing	NULL
cells	NULL
,	NULL
targets	NULL
were	NULL
treated	NULL
with	NULL
IFN-y	NULL
for	NULL
24	NULL
h	NULL
and	NULL
assayed	NULL
against	NULL
K	NULL
``	NULL
-	NULL
and	NULL
DÂ®-restricted	NULL
CTL	NULL
.	NULL

Treatment	NULL
of	NULL
d1309	NULL
(	NULL
gp19K*	NULL
)	NULL
-infected	NULL
SVHTG	NULL
(	NULL
K7	NULL
)	NULL
targets	NULL
with	NULL
IFN-y	NULL
increased	NULL
cytolysis	NULL
by	NULL
~40-fold	NULL
,	NULL
while	NULL
not	NULL
altering	NULL
the	NULL
lysis	NULL
of	NULL
d/327	NULL
(	NULL
AE3	NULL
)	NULL
-infected	NULL
targets	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

Since	NULL
gp19K	NULL
does	NULL
not	NULL
bind	NULL
to	NULL
D	NULL
``	NULL
molecules	NULL
,	NULL
IFN-y	NULL
treatment	NULL
of	NULL
SVHTI	NULL
(	NULL
D	NULL
``	NULL
)	NULL
targets	NULL
increased	NULL
the	NULL
lysis	NULL
of	NULL
both	NULL
41309-	NULL
and	NULL
di327-infected	NULL
targets	NULL
equally	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
,	NULL
presumably	NULL
due	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
to	NULL
an	NULL
increase	NULL
in	NULL
cell	NULL
surface	NULL
100	NULL
80	NULL
4	NULL
60	NULL
{	NULL
40	NULL
{	NULL
20	NULL
7	NULL
p=	NULL
``	NULL
+20	NULL
Ae	NULL
r	NULL
50:1	NULL
16:1	NULL
5:1	NULL
%	NULL
SPECIFIC	NULL
LYSIS	NULL
E	NULL
:	NULL
T	NULL
RATIO	NULL
-A-	NULL
d1801	NULL
(	NULL
E1A+	NULL
,	NULL
E1B+	NULL
)	NULL
-O-	NULL
_	NULL
Ad	NULL
2/CFTR-2	NULL
(	NULL
E1A	NULL
,	NULL
,	NULL
E18	NULL
)	NULL
--	NULL
-A	NULL
--	NULL
Ad	NULL
220FTR-T	NULL
(	NULL
E1A~	NULL
,	NULL
-D-	NULL
-	NULL
UNINFECTED	NULL
100	NULL
80	NULL
7	NULL
60	NULL
7	NULL
40	NULL
{	NULL
%	NULL
SPECIFIC	NULL
LYSIS	NULL
20	NULL
7	NULL
-20	NULL
E	NULL
:	NULL
T	NULL
RATIO	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

The	NULL
generation	NULL
of	NULL
Ad-specific	NULL
,	NULL
K*-restricted	NULL
CTL	NULL
after	NULL
i.p	NULL
.	NULL

immuni-zation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
C3H	NULL
mice	NULL
immunized	NULL
twice	NULL
i.p	NULL
.	NULL

with	NULL
Ad2	NULL
;	NULL
(	NULL
B	NULL
)	NULL
C3H	NULL
mice	NULL
immunized	NULL
twice	NULL
i.p	NULL
.	NULL

with	NULL
Ad2/CFTR-2	NULL
.	NULL

E	NULL
:	NULL
T	NULL
ratio	NULL
,	NULL
effector-to-target-cell	NULL
ratio	NULL
.	NULL

Vor	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
100	NULL
A	NULL
80	NULL
4	NULL
--	NULL
-	NULL
...	NULL
.	NULL

i	NULL
~~	NULL
L..	NULL
8	NULL
w	NULL
]	NULL
C-2	NULL
0	NULL
607	NULL
~A	NULL
o	NULL
it	NULL
o	NULL
47	NULL
wi	NULL
C.	NULL
a	NULL
o	NULL
7	NULL
o	NULL
{	NULL
-20	NULL
t	NULL
t	NULL
t	NULL
60:1	NULL
20:1	NULL
611	NULL
E	NULL
:	NULL
T	NULL
RATIO	NULL
Ad	NULL
2	NULL
(	NULL
E1A+	NULL
,	NULL
E1B+	NULL
)	NULL
-O-	NULL
_	NULL
Ad	NULL
2/CFTR-2	NULL
(	NULL
EA	NULL
,	NULL
E1B-	NULL
)	NULL
Ad	NULL
2/CFTR-7	NULL
(	NULL
E1A	NULL
Â«	NULL
,	NULL
E1B-	NULL
)	NULL
-L-	NULL
-	NULL
UNINFECTED	NULL
100	NULL
so	NULL
{	NULL
F	NULL
9	NULL
0	NULL
605	NULL
o	NULL
It	NULL
``	NULL
o	NULL
97	NULL
r	NULL
C.	NULL
m	NULL
e	NULL
20	NULL
7	NULL
o	NULL
{	NULL
+20	NULL
t	NULL
t	NULL
60:1	NULL
20:1	NULL
6:1	NULL
E	NULL
:	NULL
T	NULL
RATIO	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

The	NULL
generation	NULL
of	NULL
Ad-specific	NULL
,	NULL
K*-restricted	NULL
CTL	NULL
after	NULL
i.n	NULL
.	NULL

immuni-	NULL
zation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
C3H	NULL
mice	NULL
immunized	NULL
twice	NULL
i.n	NULL
.	NULL

with	NULL
Ad2	NULL
;	NULL
(	NULL
B	NULL
)	NULL
C3H	NULL
mice	NULL
immunized	NULL
twice	NULL
i.n	NULL
.	NULL

with	NULL
Ad2/CFTR-2	NULL
.	NULL

E	NULL
:	NULL
T	NULL
ratio	NULL
,	NULL
effector-to-target-cell	NULL
ratio	NULL
.	NULL

expression	NULL
of	NULL
the	NULL
DC	NULL
molecule	NULL
.	NULL

Overcoming	NULL
gp19K	NULL
's	NULL
suppression	NULL
of	NULL
CTL	NULL
recognition	NULL
was	NULL
necessary	NULL
because	NULL
the	NULL
many	NULL
of	NULL
the	NULL
deletion	NULL
mutants	NULL
used	NULL
in	NULL
this	NULL
study	NULL
are	NULL
on	NULL
a	NULL
gp19K	NULL
``	NULL
back-ground	NULL
.	NULL

Ad-specific	NULL
CTL	NULL
in	NULL
BALB/c	NULL
mice	NULL
recognize	NULL
E1B	NULL
as	NULL
the	NULL
immunodominant	NULL
D*	NULL
epitope	NULL
,	NULL
and	NULL
an	NULL
antigen	NULL
outside	NULL
E1	NULL
is	NULL
immunodominant	NULL
for	NULL
KC	NULL
.	NULL

To	NULL
map	NULL
the	NULL
epitope	NULL
recognized	NULL
by	NULL
D	NULL
restricted	NULL
CTL	NULL
,	NULL
BALB/c	NULL
mice	NULL
were	NULL
immunized	NULL
i.p	NULL
.	NULL

with	NULL
AdS	NULL
and	NULL
restimulated	NULL
in	NULL
vitro	NULL
with	NULL
SVBALB	NULL
(	NULL
7-27	NULL
)	NULL
fibroblasts	NULL
infected	NULL
with	NULL
d1754	NULL
(	NULL
Agp19K	NULL
)	NULL
.	NULL

The	NULL
DÂ®-restricted	NULL
CTL	NULL
response	NULL
was	NULL
analyzed	NULL
by	NULL
assaying	NULL
the	NULL
CTL	NULL
against	NULL
SVHTI	NULL
(	NULL
K	NULL
``	NULL
DC	NULL
)	NULL
targets	NULL
infected	NULL
with	NULL
E1A/E1B	NULL
deletion	NULL
mutants	NULL
.	NULL

The	NULL
D	NULL
%	NULL
-re-stricted	NULL
CTL	NULL
recognized	NULL
d/312	NULL
(	NULL
AE1A	NULL
)	NULL
targets	NULL
,	NULL
while	NULL
elimination	NULL
of	NULL
the	NULL
entire	NULL
E1	NULL
region	NULL
(	NULL
Ad2/CFTR-2	NULL
and	NULL
Ad2/CFTR-7	NULL
)	NULL
abolished	NULL
CTL	NULL
lysis	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
E1B	NULL
contains	NULL
the	NULL
immunodominant	NULL
antigen	NULL
for	NULL
the	NULL
DC	NULL
allele	NULL
.	NULL

Knowledge	NULL
of	NULL
the	NULL
location	NULL
of	NULL
the	NULL
immunodominant	NULL
antigen	NULL
for	NULL
the	NULL
response	NULL
allowed	NULL
us	NULL
to	NULL
address	NULL
whether	NULL
immunorecessive	NULL
epitopes	NULL
are	NULL
recognized	NULL
upon	NULL
multiple	NULL
inoculations	NULL
.	NULL

To	NULL
address	NULL
this	NULL
,	NULL
BALB/c	NULL
mice	NULL
were	NULL
immunized	NULL
twice	NULL
in	NULL
.	NULL

with	NULL
wild-type	NULL
Ad2	NULL
or	NULL
Ad2/CFTR-2	NULL
and	NULL
assayed	NULL
against	NULL
various	NULL
targets	NULL
.	NULL

As	NULL
with	NULL
C3H	NULL
mice	NULL
,	NULL
multiple	NULL
immunizations	NULL
did	NULL
not	NULL
induce	NULL
the	NULL
recognition	NULL
of	NULL
immunorecessive	NULL
epitopes	NULL
outside	NULL
the	NULL
E1A/E1B	NULL
region	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

DÂ®-restricted	NULL
CTL	NULL
from	NULL
multiple	NULL
Ad2	NULL
immunizations	NULL
recognized	NULL
cells	NULL
expressing	NULL
E1B	NULL
(	NULL
Fig	NULL
.	NULL

9A	NULL
)	NULL
and	NULL
when	NULL
Ad2/CFTR-2	NULL
was	NULL
used	NULL
as	NULL
the	NULL
immunizing	NULL
agent	NULL
,	NULL
no	NULL
Ad-specific	NULL
CTL	NULL
were	NULL
generated	NULL
(	NULL
Fig	NULL
.	NULL

9B	NULL
)	NULL
.	NULL

CTL	NULL
FROM	NULL
Ad	NULL
IMMUNIZATIONS	NULL
RECOGNIZE	NULL
EPITOPES	NULL
-	NULL
2281	NULL
Although	NULL
there	NULL
are	NULL
similarities	NULL
between	NULL
C3H	NULL
K*-	NULL
and	NULL
BALB/c	NULL
D*-restricted	NULL
responses	NULL
,	NULL
the	NULL
lack	NULL
of	NULL
a	NULL
D	NULL
``	NULL
immunorecessive	NULL
response	NULL
is	NULL
confounded	NULL
by	NULL
a	NULL
strong	NULL
KZ	NULL
response	NULL
which	NULL
could	NULL
mask	NULL
a	NULL
D	NULL
``	NULL
-subdominant	NULL
response	NULL
(	NULL
12	NULL
)	NULL
.	NULL

The	NULL
K	NULL
``	NULL
-restricted	NULL
CTL	NULL
response	NULL
after	NULL
i.p	NULL
.	NULL

inoculations	NULL
was	NULL
mapped	NULL
in	NULL
a	NULL
manner	NULL
similar	NULL
to	NULL
that	NULL
for	NULL
the	NULL
DC	NULL
response	NULL
,	NULL
except	NULL
that	NULL
the	NULL
targets	NULL
were	NULL
SVHTG	NULL
(	NULL
KZ	NULL
D	NULL
``	NULL
)	NULL
fibroblasts	NULL
.	NULL

Targets	NULL
infected	NULL
with	NULL
viruses	NULL
that	NULL
lack	NULL
the	NULL
E1	NULL
region	NULL
(	NULL
Ad2/CFTR-2	NULL
)	NULL
were	NULL
lysed	NULL
by	NULL
K	NULL
``	NULL
-restricted	NULL
CTL	NULL
(	NULL
Fig	NULL
.	NULL

10	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
antigen	NULL
recognized	NULL
by	NULL
K	NULL
``	NULL
-restricted	NULL
CTL	NULL
is	NULL
outside	NULL
the	NULL
E1	NULL
region	NULL
.	NULL

K	NULL
``	NULL
-restricted	NULL
effectors	NULL
also	NULL
lysed	NULL
mutants	NULL
lacking	NULL
E3	NULL
or	NULL
E4	NULL
regions	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
this	NULL
response	NULL
is	NULL
directed	NULL
toward	NULL
epitopes	NULL
within	NULL
EZ	NULL
or	NULL
the	NULL
late	NULL
region	NULL
or	NULL
that	NULL
there	NULL
are	NULL
multiple	NULL
K	NULL
``	NULL
epitopes	NULL
in	NULL
several	NULL
different	NULL
regions	NULL
.	NULL

Currently	NULL
,	NULL
no	NULL
deletion	NULL
mutants	NULL
are	NULL
available	NULL
to	NULL
define	NULL
further	NULL
the	NULL
immunodominant	NULL
K	NULL
``	NULL
antigen	NULL
.	NULL

DISCUSSION	NULL
This	NULL
report	NULL
demonstrates	NULL
that	NULL
CTL	NULL
from	NULL
mice	NULL
immunized	NULL
with	NULL
wild-type	NULL
Ad	NULL
recognize	NULL
an	NULL
immunodominant	NULL
epitope	NULL
(	NULL
s	NULL
)	NULL
within	NULL
E1A	NULL
in	NULL
association	NULL
with	NULL
D	NULL
``	NULL
,	NULL
epitopes	NULL
within	NULL
E1B	NULL
in	NULL
association	NULL
with	NULL
K*	NULL
and	NULL
D	NULL
%	NULL
,	NULL
and	NULL
non-E1	NULL
antigen	NULL
(	NULL
s	NULL
)	NULL
in	NULL
associa-	NULL
100	NULL
80	NULL
7	NULL
60	NULL
7	NULL
40	NULL
%	NULL
SPECIFIC	NULL
LYSIS	NULL
20	NULL
7	NULL
+20	NULL
t	NULL
t	NULL
t	NULL
t	NULL
E	NULL
:	NULL
T	NULL
RATIO	NULL
-I-	NULL
-	NULL
41309	NULL
(	NULL
gp19K+	NULL
)	NULL
+	NULL
IFNy	NULL
-k	NULL
-	NULL
-	NULL
d1927	NULL
(	NULL
gp19K-	NULL
)	NULL
+	NULL
IFNy	NULL
-	NULL
@	NULL
-	NULL
-	NULL
UNINFECTED	NULL
+	NULL
IFNy	NULL
-L-	NULL
41309	NULL
(	NULL
gp19K+	NULL
)	NULL
-A-	NULL
41327	NULL
(	NULL
gp19K-	NULL
)	NULL
-O-	NULL
_	NULL
uNINFECTED	NULL
80	NULL
7	NULL
60	NULL
7	NULL
40	NULL
7	NULL
20	NULL
4	NULL
%	NULL
SPECIFIC	NULL
LYSIS	NULL
+20	NULL
t	NULL
u	NULL
t	NULL
u	NULL
E	NULL
:	NULL
T	NULL
RATIO	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

IFN-y	NULL
treatment	NULL
of	NULL
targets	NULL
overcomes	NULL
gp19K	NULL
suppression	NULL
of	NULL
CTL	NULL
lysis	NULL
.	NULL

BALB/c	NULL
effectors	NULL
were	NULL
generated	NULL
by	NULL
i.p	NULL
.	NULL

injection	NULL
of	NULL
AdS	NULL
once	NULL
and	NULL
restimu-lation	NULL
in	NULL
vitro	NULL
with	NULL
SVBALB	NULL
(	NULL
K	NULL
``	NULL
D	NULL
``	NULL
)	NULL
fibroblasts	NULL
infected	NULL
with	NULL
d	NULL
{	NULL
754	NULL
(	NULL
gp19K~	NULL
)	NULL
.	NULL

Target	NULL
cells	NULL
were	NULL
either	NULL
untreated	NULL
or	NULL
treated	NULL
with	NULL
50	NULL
U	NULL
of	NULL
IFN-y	NULL
or	NULL
were	NULL
mock	NULL
treated	NULL
24	NULL
h	NULL
prior	NULL
to	NULL
assay	NULL
.	NULL

(	NULL
A	NULL
)	NULL
SVHTG	NULL
(	NULL
K	NULL
``	NULL
D	NULL
``	NULL
)	NULL
targets	NULL
;	NULL
(	NULL
B	NULL
)	NULL
SVHTI	NULL
(	NULL
KÂ®	NULL
D	NULL
``	NULL
)	NULL
targets	NULL
.	NULL

E	NULL
:	NULL
T	NULL
ratio	NULL
,	NULL
effector-to-target-cell	NULL
ratio	NULL
.	NULL

2282	NULL
SPARER	NULL
ET	NULL
AL	NULL
.	NULL

so	NULL
60	NULL
Â©	NULL
g	NULL
--	NULL
-	NULL
disoo	NULL
(	NULL
E1A+	NULL
,	NULL
E1B+	NULL
)	NULL
Â£0	NULL
u-	NULL
-i-	NULL
d12	NULL
(	NULL
E1A	NULL
,	NULL
E1B4	NULL
)	NULL
5	NULL
-O-	NULL
AdgiCFThe	NULL
(	NULL
E1A	NULL
,	NULL
ENB	NULL
)	NULL
E	NULL
.	NULL

(	NULL
E14	NULL
,	NULL
B1B	NULL
)	NULL
ce	NULL
-C-	NULL
&	NULL
a	NULL
&	NULL
~20	NULL
t	NULL
t	NULL
t	NULL
60:1	NULL
20:1	NULL
6:1	NULL
E	NULL
:	NULL
T	NULL
RATIO	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

Mapping	NULL
of	NULL
the	NULL
D	NULL
``	NULL
CTL	NULL
epitope	NULL
.	NULL

BALB/c	NULL
mice	NULL
were	NULL
immunized	NULL
i.p	NULL
.	NULL

with	NULL
Ad5	NULL
,	NULL
and	NULL
spleen	NULL
cells	NULL
were	NULL
restimulated	NULL
in	NULL
vitro	NULL
.	NULL

SVHTI	NULL
(	NULL
K	NULL
``	NULL
D	NULL
``	NULL
)	NULL
targets	NULL
were	NULL
infected	NULL
with	NULL
large	NULL
E1A/E1B	NULL
deletion	NULL
mutants	NULL
.	NULL

E	NULL
:	NULL
T	NULL
ratio	NULL
,	NULL
effector-to-target-cell	NULL
ratio	NULL
.	NULL

tion	NULL
with	NULL
KZ	NULL
.	NULL

Upon	NULL
multiple	NULL
immunizations	NULL
with	NULL
wild-type	NULL
virus	NULL
or	NULL
viruses	NULL
lacking	NULL
the	NULL
immunodominant	NULL
epitope	NULL
,	NULL
subdominant	NULL
epitopes	NULL
are	NULL
recognized	NULL
in	NULL
B10	NULL
(	NULL
D	NULL
``	NULL
)	NULL
,	NULL
but	NULL
not	NULL
in	NULL
C3H	NULL
or	NULL
BALB/c	NULL
(	NULL
D	NULL
%	NULL
allele	NULL
)	NULL
mice	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

The	NULL
location	NULL
of	NULL
the	NULL
D*-restricted	NULL
subdominant	NULL
epitopes	NULL
within	NULL
the	NULL
Ad	NULL
genome	NULL
can	NULL
not	NULL
be	NULL
defined	NULL
by	NULL
available	NULL
mutants	NULL
,	NULL
but	NULL
it	NULL
does	NULL
not	NULL
reside	NULL
within	NULL
70	NULL
604	NULL
40-4	NULL
307	NULL
207	NULL
%	NULL
SPECIFIC	NULL
LYSIS	NULL
E	NULL
:	NULL
T	NULL
RATIO	NULL
-A-	NULL
-	NULL
alsot	NULL
(	NULL
BiAs	NULL
,	NULL
E184	NULL
)	NULL
-O-	NULL
_	NULL
adaicfthe	NULL
80	NULL
40	NULL
7	NULL
20	NULL
7	NULL
o	NULL
~	NULL
(	NULL
Qï¬w	NULL
+20	NULL
t	NULL
t	NULL
60:1	NULL
20:1	NULL
6:1	NULL
E	NULL
:	NULL
T	NULL
RATIO	NULL
%	NULL
SPECIFIC	NULL
LYSIS	NULL
FIG	NULL
.	NULL

9	NULL
.	NULL

Immunorecessive	NULL
epitopes	NULL
are	NULL
not	NULL
detected	NULL
in	NULL
BALB/c	NULL
mice	NULL
.	NULL

BALB/c	NULL
mice	NULL
were	NULL
immunized	NULL
twice	NULL
i.n	NULL
.	NULL

,	NULL
and	NULL
the	NULL
in	NULL
vitro	NULL
restimulated	NULL
effectors	NULL
were	NULL
assayed	NULL
against	NULL
virally	NULL
infected	NULL
SVHTI	NULL
(	NULL
K	NULL
``	NULL
D	NULL
``	NULL
)	NULL
targets	NULL
.	NULL

(	NULL
A	NULL
)	NULL
In	NULL
vivo	NULL
immunization	NULL
with	NULL
Ad	NULL
?	NULL

;	NULL
(	NULL
B	NULL
)	NULL
in	NULL
vivo	NULL
immunization	NULL
with	NULL
Ad2/CFTR-7	NULL
.	NULL

E	NULL
:	NULL
T	NULL
ratio	NULL
,	NULL
effector-to-target-cell	NULL
ratio	NULL
.	NULL

J.	NULL
ViRoL	NULL
.	NULL

-A-	NULL
Ad	NULL
?	NULL

2	NULL
d1801	NULL
(	NULL
E1A+	NULL
,	NULL
E1B+	NULL
)	NULL
90	NULL
-	NULL
@	NULL
-	NULL
_	NULL
Ad2/CFTR-2	NULL
(	NULL
E1A-	NULL
,	NULL
E1B-	NULL
)	NULL
-I-	NULL
_	NULL
Ad2/CFTR-7	NULL
(	NULL
E1A-	NULL
,	NULL
E1B-UNINFECTED	NULL
701	NULL
w	NULL
Â®	NULL
a	NULL
H0	NULL
504	NULL
9	NULL
[	NULL
2	NULL
]	NULL
a	NULL
g	NULL
,	NULL
.	NULL

307	NULL
Â®	NULL
&	NULL
107	NULL
-10	NULL
r	NULL
r	NULL
r	NULL
r	NULL
60:1	NULL
20:1	NULL
6:1	NULL
2:1	NULL
E	NULL
:	NULL
T	NULL
RATIO	NULL
FIG	NULL
.	NULL

10	NULL
.	NULL

Mapping	NULL
of	NULL
the	NULL
epitope	NULL
recognized	NULL
by	NULL
K	NULL
``	NULL
-restricted	NULL
CTL	NULL
.	NULL

BALB/c	NULL
mice	NULL
were	NULL
inoculated	NULL
i.p	NULL
.	NULL

with	NULL
Ad5	NULL
,	NULL
and	NULL
the	NULL
in	NULL
vitro-restimulated	NULL
effectors	NULL
were	NULL
assayed	NULL
against	NULL
virally	NULL
infected	NULL
SVHTG	NULL
(	NULL
K7	NULL
D	NULL
``	NULL
)	NULL
targets	NULL
.	NULL

E	NULL
:	NULL
T	NULL
ratio	NULL
,	NULL
effector-to-target-cell	NULL
ratio	NULL
.	NULL

E1	NULL
,	NULL
E3	NULL
,	NULL
or	NULL
E4	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

For	NULL
the	NULL
K*	NULL
allele	NULL
in	NULL
C3H	NULL
mice	NULL
and	NULL
the	NULL
D	NULL
``	NULL
allele	NULL
in	NULL
BALB/c	NULL
mice	NULL
,	NULL
eliminating	NULL
the	NULL
immunodominant	NULL
antigen	NULL
(	NULL
E1B	NULL
)	NULL
from	NULL
the	NULL
inoculating	NULL
virus	NULL
effectively	NULL
eliminates	NULL
the	NULL
CTL	NULL
response	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
strategy	NULL
of	NULL
modifying	NULL
gene	NULL
therapy	NULL
vectors	NULL
to	NULL
remove	NULL
CTL	NULL
epitopes	NULL
would	NULL
be	NULL
effective	NULL
in	NULL
some	NULL
individuals	NULL
but	NULL
not	NULL
in	NULL
others	NULL
after	NULL
multiple	NULL
inoculations	NULL
.	NULL

In	NULL
the	NULL
experiments	NULL
reported	NULL
here	NULL
,	NULL
regions	NULL
of	NULL
the	NULL
virus	NULL
containing	NULL
CTL	NULL
epitopes	NULL
were	NULL
identified	NULL
by	NULL
deletion	NULL
mapping	NULL
.	NULL

That	NULL
is	NULL
,	NULL
target	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
viruses	NULL
that	NULL
delete	NULL
regions	NULL
of	NULL
the	NULL
viral	NULL
genome	NULL
and	NULL
tested	NULL
for	NULL
loss	NULL
of	NULL
CTL	NULL
recognition	NULL
.	NULL

Several	NULL
assumptions	NULL
underlie	NULL
this	NULL
approach	NULL
.	NULL

First	NULL
,	NULL
it	NULL
was	NULL
assumed	NULL
that	NULL
the	NULL
CTL	NULL
response	NULL
would	NULL
be	NULL
directed	NULL
against	NULL
one	NULL
or	NULL
a	NULL
very	NULL
few	NULL
dominant	NULL
epitopes	NULL
.	NULL

Such	NULL
preferential	NULL
responses	NULL
to	NULL
dominant	NULL
epitopes	NULL
despite	NULL
the	NULL
apparent	NULL
availability	NULL
of	NULL
many	NULL
potential	NULL
epitopes	NULL
have	NULL
been	NULL
seen	NULL
with	NULL
other	NULL
virus	NULL
systems	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
see	NULL
references	NULL
22	NULL
,	NULL
25	NULL
,	NULL
and	NULL
26	NULL
)	NULL
,	NULL
although	NULL
the	NULL
mechanism	NULL
of	NULL
epitope	NULL
dominance	NULL
remains	NULL
unknown	NULL
.	NULL

Were	NULL
CTL	NULL
to	NULL
recognize	NULL
many	NULL
different	NULL
epitopes	NULL
from	NULL
the	NULL
viral	NULL
genome	NULL
,	NULL
cells	NULL
infected	NULL
with	NULL
deletion	NULL
mutants	NULL
lacking	NULL
only	NULL
some	NULL
would	NULL
not	NULL
be	NULL
distinguished	NULL
from	NULL
the	NULL
wild-type	NULL
in	NULL
sensitivity	NULL
to	NULL
CTL	NULL
lysis	NULL
.	NULL

In	NULL
earlier	NULL
studies	NULL
,	NULL
we	NULL
found	NULL
that	NULL
after	NULL
a	NULL
single	NULL
immunization	NULL
with	NULL
Ad	NULL
,	NULL
B10	NULL
mice	NULL
produced	NULL
CTL	NULL
that	NULL
recognized	NULL
only	NULL
epitopes	NULL
within	NULL
E1A	NULL
(	NULL
27	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
CTL	NULL
to	NULL
Ad	NULL
would	NULL
be	NULL
relatively	NULL
restricted	NULL
in	NULL
their	NULL
epitope	NULL
selection	NULL
.	NULL

TABLE	NULL
1	NULL
.	NULL

Summary	NULL
of	NULL
mouse	NULL
CTL	NULL
responses	NULL
to	NULL
group	NULL
C	NULL
Ads	NULL
Dominant	NULL
Immunorecessive	NULL
Mouse	NULL
type	NULL
epitope	NULL
(	NULL
s	NULL
)	NULL
epitope	NULL
(	NULL
s	NULL
)	NULL
C57BL/10	NULL
(	NULL
4-25	NULL
)	NULL
K	NULL
None	NULL
None	NULL
D	NULL
``	NULL
E1A	NULL
Non-E1	NULL
,	NULL
-E3	NULL
,	NULL
and	NULL
-E4	NULL
C3H	NULL
(	NULL
H-2	NULL
``	NULL
)	NULL
K*	NULL
E1B	NULL
+None	NULL
D*	NULL
None	NULL
None	NULL
BALB/c	NULL
(	NULL
H-2	NULL
``	NULL
)	NULL
K	NULL
Non-E1	NULL
,	NULL
-E3	NULL
,	NULL
and	NULL
-F4	NULL
_	NULL
-*	NULL
D	NULL
E1B	NULL
None	NULL
``	NULL
-	NULL
,	NULL
undetermined	NULL
.	NULL

Vor	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
Second	NULL
,	NULL
it	NULL
was	NULL
assumed	NULL
in	NULL
cases	NULL
in	NULL
which	NULL
CTL	NULL
failed	NULL
to	NULL
lyse	NULL
mutant-infected	NULL
cells	NULL
that	NULL
the	NULL
region	NULL
deleted	NULL
from	NULL
the	NULL
virus	NULL
contained	NULL
the	NULL
epitope	NULL
(	NULL
s	NULL
)	NULL
recognized	NULL
by	NULL
CTL	NULL
.	NULL

During	NULL
virus	NULL
infection	NULL
,	NULL
transcription	NULL
of	NULL
many	NULL
viral	NULL
genes	NULL
depends	NULL
on	NULL
prior	NULL
expression	NULL
of	NULL
other	NULL
viral	NULL
proteins	NULL
,	NULL
notably	NULL
those	NULL
encoded	NULL
within	NULL
E1A	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
E1A	NULL
proteins	NULL
is	NULL
required	NULL
for	NULL
the	NULL
timely	NULL
transcription	NULL
of	NULL
all	NULL
other	NULL
viral	NULL
genes	NULL
after	NULL
infection	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Nonetheless	NULL
,	NULL
there	NULL
are	NULL
several	NULL
reasons	NULL
to	NULL
believe	NULL
that	NULL
deleting	NULL
E1A	NULL
does	NULL
not	NULL
lead	NULL
to	NULL
functional	NULL
removal	NULL
of	NULL
CTL	NULL
epitopes	NULL
derived	NULL
from	NULL
genes	NULL
outside	NULL
E1A	NULL
.	NULL

First	NULL
is	NULL
our	NULL
previous	NULL
observation	NULL
(	NULL
27	NULL
)	NULL
,	NULL
also	NULL
reported	NULL
here	NULL
,	NULL
that	NULL
cells	NULL
infected	NULL
with	NULL
dl312	NULL
,	NULL
which	NULL
lack	NULL
all	NULL
E1A	NULL
transactivation	NULL
functions	NULL
,	NULL
are	NULL
recognized	NULL
by	NULL
CTL	NULL
from	NULL
C3H	NULL
and	NULL
BALB/c	NULL
mice	NULL
.	NULL

That	NULL
these	NULL
CTL	NULL
are	NULL
not	NULL
recognizing	NULL
residual	NULL
E1A	NULL
epitopes	NULL
was	NULL
confirmed	NULL
by	NULL
their	NULL
failure	NULL
to	NULL
lyse	NULL
transfected	NULL
syngeneic	NULL
cells	NULL
expressing	NULL
E1A	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
some	NULL
non-E1A	NULL
genes	NULL
must	NULL
be	NULL
expressed	NULL
at	NULL
levels	NULL
sufficient	NULL
to	NULL
permit	NULL
CTL	NULL
recognition	NULL
.	NULL

In	NULL
our	NULL
studies	NULL
,	NULL
infections	NULL
with	NULL
E1A-deleted	NULL
viruses	NULL
were	NULL
performed	NULL
at	NULL
high	NULL
multiplicity	NULL
of	NULL
infection	NULL
and	NULL
allowed	NULL
proceeding	NULL
for	NULL
40	NULL
to	NULL
48	NULL
h	NULL
,	NULL
under	NULL
which	NULL
conditions	NULL
viral	NULL
mRNAs	NULL
(	NULL
24	NULL
)	NULL
and	NULL
early	NULL
proteins	NULL
(	NULL
9	NULL
)	NULL
slowly	NULL
accumulate	NULL
.	NULL

El-deleted	NULL
viruses	NULL
have	NULL
even	NULL
been	NULL
shown	NULL
to	NULL
transcribe	NULL
late	NULL
genes	NULL
in	NULL
infected	NULL
mouse	NULL
lungs	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Surprisingly	NULL
,	NULL
we	NULL
find	NULL
that	NULL
CTL	NULL
recognize	NULL
epitopes	NULL
from	NULL
E1A-deleted	NULL
viruses	NULL
at	NULL
even	NULL
very	NULL
early	NULL
times	NULL
postinfection	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
reason	NULL
for	NULL
this	NULL
apparent	NULL
paradox	NULL
lies	NULL
in	NULL
the	NULL
exquisite	NULL
sensitivity	NULL
of	NULL
CTL	NULL
to	NULL
viral	NULL
peptides	NULL
.	NULL

Kageyama	NULL
et	NULL
al	NULL
.	NULL

(	NULL
19	NULL
)	NULL
have	NULL
reported	NULL
that	NULL
some	NULL
CTL	NULL
require	NULL
expression	NULL
of	NULL
fewer	NULL
than	NULL
10	NULL
peptide-	NULL
MHC	NULL
molecules	NULL
per	NULL
target	NULL
cell	NULL
for	NULL
recognition	NULL
and	NULL
cytolysis	NULL
to	NULL
occur	NULL
.	NULL

Thus	NULL
,	NULL
even	NULL
very	NULL
low	NULL
levels	NULL
of	NULL
virus	NULL
gene	NULL
expression	NULL
are	NULL
sufficient	NULL
to	NULL
produce	NULL
a	NULL
CTL	NULL
target	NULL
.	NULL

Indeed	NULL
,	NULL
CTL	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
recognize	NULL
epitopes	NULL
derived	NULL
from	NULL
genes	NULL
with	NULL
no	NULL
promoter	NULL
or	NULL
translation	NULL
start	NULL
site	NULL
or	NULL
after	NULL
a	NULL
termination	NULL
codon	NULL
(	NULL
5	NULL
,	NULL
21	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
Ad	NULL
proteins	NULL
produced	NULL
in	NULL
infected	NULL
cells	NULL
,	NULL
even	NULL
under	NULL
conditions	NULL
in	NULL
which	NULL
their	NULL
normal	NULL
regulation	NULL
has	NULL
been	NULL
interrupted	NULL
due	NULL
to	NULL
the	NULL
lack	NULL
of	NULL
regulatory	NULL
functions	NULL
such	NULL
as	NULL
E1A	NULL
,	NULL
will	NULL
certainly	NULL
be	NULL
sufficient	NULL
to	NULL
allow	NULL
CTL	NULL
recognition	NULL
.	NULL

Our	NULL
findings	NULL
on	NULL
E1B	NULL
immunodominance	NULL
for	NULL
the	NULL
K*	NULL
allele	NULL
are	NULL
in	NULL
apparent	NULL
contradiction	NULL
to	NULL
reports	NULL
by	NULL
Zhang	NULL
et	NULL
al	NULL
.	NULL

(	NULL
45	NULL
)	NULL
and	NULL
Yang	NULL
et	NULL
al	NULL
.	NULL

(	NULL
41	NULL
)	NULL
.	NULL

Zhang	NULL
et	NULL
al	NULL
.	NULL

mapped	NULL
the	NULL
immunodominant	NULL
epitope	NULL
in	NULL
CBA	NULL
(	NULL
H-2*	NULL
)	NULL
mice	NULL
to	NULL
E1A	NULL
,	NULL
but	NULL
we	NULL
(	NULL
reference	NULL
27	NULL
and	NULL
this	NULL
report	NULL
)	NULL
find	NULL
that	NULL
K*-restricted	NULL
CTL	NULL
do	NULL
not	NULL
recognize	NULL
an	NULL
E1A	NULL
transfectant	NULL
and	NULL
do	NULL
lyse	NULL
targets	NULL
infected	NULL
with	NULL
d/312	NULL
which	NULL
lacks	NULL
E1A	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
Yang	NULL
et	NULL
al	NULL
.	NULL

generated	NULL
Ad-specific	NULL
CTL	NULL
in	NULL
CBA	NULL
mice	NULL
(	NULL
-2	NULL
``	NULL
)	NULL
after	NULL
immunizing	NULL
only	NULL
once	NULL
i.n	NULL
.	NULL

with	NULL
a	NULL
CFTR	NULL
vector	NULL
that	NULL
lacked	NULL
E1	NULL
.	NULL

In	NULL
our	NULL
study	NULL
,	NULL
C3H	NULL
(	NULL
H-2*	NULL
)	NULL
mice	NULL
did	NULL
not	NULL
mount	NULL
a	NULL
CTL	NULL
response	NULL
against	NULL
Ad	NULL
CFTR	NULL
vectors	NULL
even	NULL
after	NULL
two	NULL
i.n	NULL
.	NULL

inoculations	NULL
.	NULL

One	NULL
possible	NULL
explanation	NULL
for	NULL
these	NULL
apparent	NULL
discrepancies	NULL
is	NULL
that	NULL
genetic	NULL
differences	NULL
between	NULL
CBA	NULL
and	NULL
C3H	NULL
mice	NULL
or	NULL
differences	NULL
in	NULL
the	NULL
vector	NULL
backbone	NULL
(	NULL
20	NULL
)	NULL
resulted	NULL
in	NULL
different	NULL
CTL	NULL
responses	NULL
.	NULL

As	NULL
we	NULL
have	NULL
seen	NULL
with	NULL
the	NULL
CTL	NULL
response	NULL
in	NULL
Ad-infected	NULL
B10	NULL
and	NULL
B6	NULL
mice	NULL
(	NULL
36a	NULL
)	NULL
,	NULL
even	NULL
substrains	NULL
of	NULL
mice	NULL
may	NULL
have	NULL
slightly	NULL
different	NULL
immunodominant	NULL
responses	NULL
.	NULL

Another	NULL
possible	NULL
explanation	NULL
is	NULL
that	NULL
differences	NULL
between	NULL
in	NULL
vitro	NULL
stimulators	NULL
could	NULL
lead	NULL
to	NULL
the	NULL
expansion	NULL
of	NULL
different	NULL
CTL	NULL
populations	NULL
.	NULL

Our	NULL
secondary	NULL
in	NULL
vitro	NULL
stimulators	NULL
were	NULL
Ad-infected	NULL
,	NULL
SV-40	NULL
transformed	NULL
fibroblasts	NULL
,	NULL
while	NULL
both	NULL
of	NULL
the	NULL
other	NULL
groups	NULL
used	NULL
Ad-infected	NULL
splenocytes	NULL
as	NULL
stim-ulators	NULL
.	NULL

This	NULL
could	NULL
have	NULL
led	NULL
to	NULL
the	NULL
generation	NULL
of	NULL
CD4	NULL
*	NULL
class	NULL
T-restricted	NULL
killers	NULL
(	NULL
42	NULL
)	NULL
or	NULL
to	NULL
the	NULL
expansion	NULL
of	NULL
CTL	NULL
that	NULL
recognize	NULL
E1A	NULL
instead	NULL
of	NULL
E1B	NULL
.	NULL

Whether	NULL
subtle	NULL
differences	NULL
in	NULL
antigen	NULL
processing	NULL
and	NULL
presentation	NULL
could	NULL
explain	NULL
these	NULL
differences	NULL
remains	NULL
to	NULL
be	NULL
tested	NULL
.	NULL

The	NULL
findings	NULL
from	NULL
this	NULL
study	NULL
offer	NULL
some	NULL
hope	NULL
for	NULL
modification	NULL
of	NULL
Ad	NULL
gene	NULL
therapy	NULL
vectors	NULL
.	NULL

It	NULL
may	NULL
be	NULL
possible	NULL
to	NULL
alter	NULL
the	NULL
CTL	NULL
response	NULL
(	NULL
as	NULL
in	NULL
C3H	NULL
mice	NULL
or	NULL
DC	NULL
in	NULL
BALB/c	NULL
mice	NULL
)	NULL
by	NULL
CTL	NULL
FROM	NULL
Ad	NULL
IMMUNIZATIONS	NULL
RECOGNIZE	NULL
EPITOPES	NULL
-	NULL
2283	NULL
creating	NULL
vectors	NULL
that	NULL
lack	NULL
the	NULL
immunodominant	NULL
antigen	NULL
or	NULL
vectors	NULL
with	NULL
altered	NULL
anchor-subanchor	NULL
residues	NULL
in	NULL
the	NULL
antigenic	NULL
regions	NULL
.	NULL

Of	NULL
course	NULL
,	NULL
the	NULL
CTL	NULL
response	NULL
is	NULL
likely	NULL
to	NULL
vary	NULL
within	NULL
the	NULL
diverse	NULL
human	NULL
population	NULL
,	NULL
thus	NULL
making	NULL
epitope	NULL
mapping	NULL
more	NULL
complicated	NULL
.	NULL

Even	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
immunodominant	NULL
antigen	NULL
(	NULL
s	NULL
)	NULL
,	NULL
repeat	NULL
administrations	NULL
could	NULL
cause	NULL
the	NULL
generation	NULL
of	NULL
CTL	NULL
against	NULL
subdominant	NULL
epitopes	NULL
,	NULL
as	NULL
was	NULL
observed	NULL
with	NULL
B10	NULL
mice	NULL
.	NULL

Another	NULL
possible	NULL
method	NULL
for	NULL
preventing	NULL
CTL	NULL
recognition	NULL
would	NULL
be	NULL
alterations	NULL
in	NULL
the	NULL
Ad	NULL
genome	NULL
such	NULL
that	NULL
only	NULL
minimal	NULL
levels	NULL
of	NULL
Ad	NULL
proteins	NULL
are	NULL
produced	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
AE2	NULL
[	NULL
10	NULL
,	NULL
11	NULL
]	NULL
or	NULL
AE4	NULL
[	NULL
2	NULL
]	NULL
)	NULL
.	NULL

Although	NULL
very	NULL
few	NULL
peptide-MHC	NULL
complexes	NULL
are	NULL
necessary	NULL
for	NULL
CTL	NULL
lysis	NULL
,	NULL
the	NULL
requirement	NULL
for	NULL
CTL	NULL
activation	NULL
and	NULL
expansion	NULL
depends	NULL
on	NULL
the	NULL
accessory	NULL
molecules	NULL
and	NULL
cell	NULL
type	NULL
of	NULL
the	NULL
presenting	NULL
cell	NULL
(	NULL
32	NULL
)	NULL
.	NULL

This	NULL
could	NULL
vary	NULL
depending	NULL
on	NULL
the	NULL
route	NULL
(	NULL
intravenous	NULL
verse	NULL
i.n	NULL
.	NULL
)	NULL

and	NULL
dose	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
a	NULL
single	NULL
i.p	NULL
.	NULL

inoculation	NULL
in	NULL
B10	NULL
mice	NULL
leads	NULL
to	NULL
the	NULL
expansion	NULL
of	NULL
CTL	NULL
that	NULL
recognize	NULL
E1A	NULL
as	NULL
the	NULL
immunodominant	NULL
antigen	NULL
,	NULL
while	NULL
others	NULL
(	NULL
20	NULL
,	NULL
38	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
a	NULL
larger	NULL
i.n	NULL
.	NULL

dose	NULL
leads	NULL
to	NULL
the	NULL
generation	NULL
of	NULL
CTL	NULL
that	NULL
also	NULL
recognize	NULL
the	NULL
subdominant	NULL
non-E1	NULL
antigen	NULL
.	NULL

Only	NULL
after	NULL
multiple	NULL
i.p	NULL
.	NULL

inoculations	NULL
were	NULL
CTL	NULL
that	NULL
recognized	NULL
the	NULL
subdominant	NULL
epitope	NULL
generated	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
seems	NULL
that	NULL
lower	NULL
doses	NULL
mulitple	NULL
times	NULL
or	NULL
a	NULL
single	NULL
larger	NULL
dose	NULL
can	NULL
lead	NULL
to	NULL
the	NULL
recognition	NULL
of	NULL
subdominant	NULL
antigens	NULL
.	NULL

Expression	NULL
vectors	NULL
that	NULL
minimize	NULL
the	NULL
expression	NULL
of	NULL
viral	NULL
antigens	NULL
could	NULL
prevent	NULL
the	NULL
threshold	NULL
needed	NULL
for	NULL
CTL	NULL
activation	NULL
and	NULL
expansion	NULL
.	NULL

These	NULL
approaches	NULL
are	NULL
currently	NULL
being	NULL
investigated	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
William	NULL
S.	NULL
M.	NULL
Wold	NULL
,	NULL
Terry	NULL
W.	NULL
Hermiston	NULL
,	NULL
and	NULL
David	NULL
Ornellas	NULL
for	NULL
providing	NULL
the	NULL
viruses	NULL
used	NULL
in	NULL
this	NULL
study	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Jennifer	NULL
Hull	NULL
for	NULL
excellent	NULL
technical	NULL
assistance	NULL
.	NULL

This	NULL
work	NULL
was	NULL
funded	NULL
by	NULL
NIH	NULL
grant	NULL
CA58736	NULL
and	NULL
a	NULL
grant	NULL
from	NULL
Genzyme	NULL
Corp.	NULL
REFERENCES	NULL
1	NULL
.	NULL

Anderson	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
Paabo	NULL
,	NULL
T.	NULL
Nilsson	NULL
,	NULL
and	NULL
P.	NULL
Peterson	NULL
.	NULL

1985	NULL
.	NULL

Impaired	NULL
intra-cellular	NULL
transport	NULL
of	NULL
class	NULL
I	NULL
MHC	NULL
antigens	NULL
as	NULL
a	NULL
possible	NULL
means	NULL
for	NULL
adenovirus	NULL
to	NULL
evade	NULL
immune	NULL
surveillance	NULL
.	NULL

Cell	NULL
43:215-222	NULL
.	NULL

2	NULL
.	NULL

Armentano	NULL
,	NULL
D.	NULL
,	NULL
C.	NULL
C.	NULL
Sookdeo	NULL
,	NULL
K.	NULL
M.	NULL
Hehir	NULL
,	NULL
R.	NULL
J.	NULL
Gregory	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
St.	NULL
George	NULL
,	NULL
G.	NULL
A	NULL
.	NULL

Prince	NULL
,	NULL
S.	NULL
C.	NULL
Wadsworth	NULL
,	NULL
and	NULL
A.	NULL
E.	NULL
Smith	NULL
.	NULL

1995	NULL
.	NULL

Characterization	NULL
of	NULL
an	NULL
adenovirus	NULL
gene	NULL
transfer	NULL
vector	NULL
containing	NULL
an	NULL
E4	NULL
deletion	NULL
.	NULL

Hum	NULL
.	NULL

Gen.	NULL
Ther	NULL
.	NULL

6:1343-1353	NULL
.	NULL

3	NULL
.	NULL

Bennink	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
J.	NULL
W.	NULL
Yewdell	NULL
,	NULL
G.	NULL
L.	NULL
Smith	NULL
,	NULL
and	NULL
B.	NULL
Moss	NULL
.	NULL

1986	NULL
.	NULL

Recognition	NULL
of	NULL
cloned	NULL
influenza	NULL
virus	NULL
hemagglutinin	NULL
gene	NULL
products	NULL
by	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

57:786-791	NULL
.	NULL

4	NULL
.	NULL

Challberg	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
and	NULL
G.	NULL
Ketner	NULL
.	NULL

1981	NULL
.	NULL

Deletion	NULL
mutants	NULL
of	NULL
adenovirus	NULL
2	NULL
:	NULL
isolation	NULL
and	NULL
initial	NULL
characterization	NULL
of	NULL
virus	NULL
carrying	NULL
mutations	NULL
near	NULL
the	NULL
right	NULL
end	NULL
of	NULL
the	NULL
viral	NULL
genome	NULL
.	NULL

Virology	NULL
114:196-209	NULL
.	NULL

5	NULL
.	NULL

Chomez	NULL
,	NULL
P.	NULL
,	NULL
E.	NULL
De	NULL
Plaen	NULL
,	NULL
A	NULL
.	NULL

Van	NULL
Pel	NULL
,	NULL
C.	NULL
De	NULL
Smet	NULL
,	NULL
J.-P.	NULL
Szikora	NULL
,	NULL
C.	NULL
Lurquin	NULL
,	NULL
A.M.	NULL
Lebacz-Verheyden	NULL
,	NULL
and	NULL
T.	NULL
Boon	NULL
.	NULL

1992	NULL
.	NULL

Efficient	NULL
expression	NULL
of	NULL
tum~	NULL
antigen	NULL
P91A	NULL
by	NULL
transfected	NULL
subgenic	NULL
fragments	NULL
.	NULL

Immunogenetics	NULL
35:241-252	NULL
.	NULL

6	NULL
.	NULL

Clayman	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
A.	NULL
K.	NULL
el-Naggar	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Roth	NULL
,	NULL
W.	NULL
W.	NULL
Zhang	NULL
,	NULL
H.	NULL
Goepfert	NULL
,	NULL
D.	NULL
L.	NULL
Taylor	NULL
,	NULL
and	NULL
T.	NULL
J.	NULL
Liu	NULL
.	NULL

1995	NULL
.	NULL

In	NULL
vivo	NULL
molecular	NULL
therapy	NULL
with	NULL
p53	NULL
adenovirus	NULL
for	NULL
microscopic	NULL
residual	NULL
head	NULL
and	NULL
neck	NULL
squamous	NULL
carcinoma	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

55:1-6	NULL
.	NULL

7	NULL
.	NULL

Cox	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
J.	NULL
W.	NULL
Yewdell	NULL
,	NULL
L.	NULL
C.	NULL
Eisenlobhr	NULL
,	NULL
P.	NULL
R.	NULL
Johnson	NULL
,	NULL
and	NULL
J.	NULL
R.	NULL
Bennink	NULL
.	NULL

1990	NULL
.	NULL

Antigen	NULL
presentation	NULL
requires	NULL
transport	NULL
of	NULL
MHC	NULL
class	NULL
I	NULL
molecules	NULL
from	NULL
the	NULL
endoplasmic	NULL
reticulum	NULL
.	NULL

Science	NULL
247:715-8	NULL
.	NULL

8	NULL
.	NULL

Doherty	NULL
,	NULL
P.	NULL
,	NULL
W.	NULL
Allan	NULL
,	NULL
and	NULL
M.	NULL
Eichelberger	NULL
.	NULL

1992	NULL
.	NULL

Roles	NULL
of	NULL
Â«	NULL
B	NULL
and	NULL
y8	NULL
T	NULL
cell	NULL
subsets	NULL
in	NULL
viral	NULL
immunity	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

10:123-151	NULL
.	NULL

9	NULL
.	NULL

Duerksen-Hughes	NULL
,	NULL
P.	NULL
,	NULL
W.	NULL
S.	NULL
Wold	NULL
,	NULL
and	NULL
L.	NULL
R.	NULL
Gooding	NULL
.	NULL

1989	NULL
.	NULL

Adenovirus	NULL
E1A	NULL
renders	NULL
infected	NULL
cells	NULL
sensitive	NULL
to	NULL
cytolysis	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

143:4193-4200	NULL
.	NULL

10	NULL
.	NULL

Engelhardt	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
L.	NULL
Litzky	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Wilson	NULL
.	NULL

1994	NULL
.	NULL

Prolonged	NULL
transgene	NULL
expression	NULL
in	NULL
cotton	NULL
rat	NULL
lung	NULL
with	NULL
recombinant	NULL
adenoviruses	NULL
defective	NULL
in	NULL
E2a	NULL
.	NULL

Hum	NULL
.	NULL

Gene	NULL
Ther	NULL
.	NULL

5:1217-1229	NULL
.	NULL

11	NULL
.	NULL

Engelhardt	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
X.	NULL
Ye	NULL
,	NULL
B.	NULL
Doranz	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Wilson	NULL
.	NULL

1994	NULL
.	NULL

Ablation	NULL
of	NULL
E2A	NULL
in	NULL
recombinant	NULL
adenoviruses	NULL
improves	NULL
transgene	NULL
persistence	NULL
and	NULL
decreases	NULL
inflammatory	NULL
response	NULL
in	NULL
mouse	NULL
liver	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:6196-6200	NULL
.	NULL

12	NULL
.	NULL

Gooding	NULL
,	NULL
L.	NULL
R.	NULL
1980	NULL
.	NULL

Anomalous	NULL
behavior	NULL
of	NULL
H-2Kb	NULL
in	NULL
immunity	NULL
to	NULL
syngeneic	NULL
SV40	NULL
transformed	NULL
cells	NULL
:	NULL
evidence	NULL
for	NULL
cytotoxic	NULL
T	NULL
cell	NULL
recognition	NULL
of	NULL
2284	NULL
13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

SPARER	NULL
ET	NULL
AL	NULL
.	NULL

H-2/SV40	NULL
membrane	NULL
antigen	NULL
complexes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

124:1612-1619	NULL
.	NULL

Gooding	NULL
,	NULL
L.	NULL
R.	NULL
1977	NULL
.	NULL

Specificities	NULL
of	NULL
killing	NULL
by	NULL
cytotoxic	NULL
lymphocytes	NULL
generated	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
to	NULL
syngeneic	NULL
SV40	NULL
transformed	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

118:920-927	NULL
.	NULL

Gooding	NULL
,	NULL
L.	NULL
R.	NULL
1979	NULL
.	NULL

Specificities	NULL
of	NULL
killing	NULL
by	NULL
T	NULL
lymphocytes	NULL
generated	NULL
against	NULL
syngeneic	NULL
SV40	NULL
transformants	NULL
:	NULL
studies	NULL
employing	NULL
recombinants	NULL
within	NULL
the	NULL
H-2	NULL
complex	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

122:1002-1008	NULL
.	NULL

Gooding	NULL
,	NULL
L.	NULL
R.	NULL
,	NULL
L.	NULL
W.	NULL
Elmore	NULL
,	NULL
A.	NULL
E.	NULL
Tollefson	NULL
,	NULL
H.	NULL
A.	NULL
Brady	NULL
,	NULL
and	NULL
W.	NULL
S.	NULL
Wold	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
14,700	NULL
MW	NULL
protein	NULL
from	NULL
the	NULL
E3	NULL
region	NULL
of	NULL
adenovirus	NULL
inhibits	NULL
cytolysis	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

Cell	NULL
53:341-346	NULL
.	NULL

Green	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
W.	NULL
S.	NULL
Wold	NULL
.	NULL

1979	NULL
.	NULL

Human	NULL
adenoviruses	NULL
:	NULL
growth	NULL
,	NULL
purification	NULL
,	NULL
and	NULL
transfection	NULL
assay	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

58:425-435	NULL
.	NULL

Herz	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
R.	NULL
D.	NULL
Gerard	NULL
.	NULL

1993	NULL
.	NULL

Adcnovirus-mediated	NULL
transfer	NULL
of	NULL
low	NULL
density	NULL
lipoprotein	NULL
receptor	NULL
gene	NULL
acutely	NULL
accelerates	NULL
cholesterol	NULL
clearance	NULL
in	NULL
normal	NULL
mice	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:2812-2816	NULL
.	NULL

Jones	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
T.	NULL
Shenk	NULL
.	NULL

1979	NULL
.	NULL

Isolation	NULL
of	NULL
adenovirus	NULL
type	NULL
5	NULL
host	NULL
range	NULL
deletion	NULL
mutants	NULL
defective	NULL
for	NULL
transformation	NULL
of	NULL
rat	NULL
embryo	NULL
cells	NULL
.	NULL

Cell	NULL
17	NULL
:	NULL
683-689	NULL
.	NULL

Kageyama	NULL
,	NULL
S.	NULL
,	NULL
T.	NULL
Tsomides	NULL
,	NULL
Y.	NULL
Sykuleyv	NULL
,	NULL
and	NULL
H.	NULL
Eisen	NULL
.	NULL

1995	NULL
.	NULL

Variations	NULL
in	NULL
the	NULL
number	NULL
of	NULL
peptide-MHC	NULL
class	NULL
I	NULL
complexes	NULL
required	NULL
to	NULL
activate	NULL
cytotoxic	NULL
T	NULL
cell	NULL
responses	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:567-576	NULL
.	NULL

Kaplan	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
D.	NULL
Armentano	NULL
,	NULL
T.	NULL
E.	NULL
Sparer	NULL
,	NULL
S.	NULL
G.	NULL
Wynn	NULL
,	NULL
P.	NULL
A.	NULL
Peterson	NULL
,	NULL
S.	NULL
C.	NULL
Wadsworth	NULL
,	NULL
K.	NULL
Couture	NULL
,	NULL
S.	NULL
E.	NULL
Pennington	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
St.	NULL
George	NULL
,	NULL
L.	NULL
R.	NULL
Gooding	NULL
,	NULL
and	NULL
A.	NULL
E.	NULL
Smith	NULL
.	NULL

1997	NULL
.	NULL

Characterization	NULL
of	NULL
factors	NULL
involved	NULL
in	NULL
modulating	NULL
persistence	NULL
of	NULL
transgene	NULL
expression	NULL
from	NULL
recombinant	NULL
adenovirus	NULL
in	NULL
the	NULL
mouse	NULL
lung	NULL
.	NULL

Hum	NULL
.	NULL

Gene	NULL
Ther	NULL
.	NULL

845-56	NULL
.	NULL

Malarkannan	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
Afkarian	NULL
,	NULL
and	NULL
N.	NULL
Shastri	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
rare	NULL
cryptic	NULL
translation	NULL
product	NULL
is	NULL
presented	NULL
by	NULL
K	NULL
``	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
I	NULL
molecule	NULL
to	NULL
alloreactive	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182:1739-1750	NULL
.	NULL

Moskophidis	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Zinkernagel	NULL
.	NULL

1995	NULL
.	NULL

Immunobiology	NULL
of	NULL
cytotoxic	NULL
T-cell	NULL
escape	NULL
mutants	NULL
of	NULL
lymphocytic	NULL
choriomeningitis	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69	NULL
:	NULL
2187-2193	NULL
.	NULL

Mullbacher	NULL
,	NULL
A.	NULL
,	NULL
A.	NULL
J.	NULL
Bellett	NULL
,	NULL
and	NULL
R.	NULL
T.	NULL
Hla	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
murine	NULL
cellular	NULL
immune	NULL
response	NULL
to	NULL
adenovirus	NULL
type	NULL
5	NULL
.	NULL

Immunol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

67:31-39	NULL
.	NULL

Nevins	NULL
,	NULL
J.	NULL
R.	NULL
1981	NULL
.	NULL

Mechanism	NULL
of	NULL
activation	NULL
of	NULL
early	NULL
viral	NULL
transcription	NULL
by	NULL
the	NULL
adenovirus	NULL
E1A	NULL
gene	NULL
product	NULL
.	NULL

Cell	NULL
26:213-220.	NULL
.	NULL

Nowak	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
R.	NULL
M.	NULL
May	NULL
,	NULL
R.	NULL
E.	NULL
Phillips	NULL
,	NULL
S.	NULL
Rowland-Jones	NULL
,	NULL
D.	NULL
G.	NULL
Lalloo	NULL
,	NULL
S.	NULL
McAdam	NULL
,	NULL
P.	NULL
Klenerman	NULL
,	NULL
B.	NULL
Koppe	NULL
,	NULL
K.	NULL
Sigmund	NULL
,	NULL
C.	NULL
R.	NULL
Bangham	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
.	NULL

Antigenic	NULL
oscillations	NULL
and	NULL
shifting	NULL
immunodominance	NULL
in	NULL
HIV-1	NULL
infections	NULL
.	NULL

Nature	NULL
375:606-611	NULL
.	NULL

Oldstone	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
J.	NULL
L.	NULL
Whitton	NULL
,	NULL
H.	NULL
Lewicki	NULL
,	NULL
and	NULL
A.	NULL
Tishon	NULL
.	NULL

1988	NULL
.	NULL

Fine	NULL
dissection	NULL
of	NULL
a	NULL
nine	NULL
amino	NULL
acid	NULL
glycoprotein	NULL
epitope	NULL
,	NULL
a	NULL
major	NULL
determinant	NULL
recognized	NULL
by	NULL
lymphocytic	NULL
choriomeningitis	NULL
virus-specific	NULL
class	NULL
T-restricted	NULL
H-2D	NULL
``	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

168:559-570	NULL
.	NULL

26a.Fawle	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
and	NULL
L.	NULL
R.	NULL
Gooding	NULL
.	NULL

Unpublished	NULL
data	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

Rawle	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
B	NULL
.	NULL

B.	NULL
Knowles	NULL
,	NULL
R.	NULL
P.	NULL
Ricciardi	NULL
,	NULL
V.	NULL
Brahmacheri	NULL
,	NULL
P.	NULL
Duerksen-Hughes	NULL
,	NULL
W.	NULL
S.	NULL
Wold	NULL
,	NULL
and	NULL
L.	NULL
R.	NULL
Gooding	NULL
.	NULL

1991	NULL
.	NULL

Specificity	NULL
of	NULL
the	NULL
mouse	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
response	NULL
to	NULL
adenovirus	NULL
5	NULL
.	NULL

E1A	NULL
is	NULL
immunodominant	NULL
in	NULL
H-2b	NULL
,	NULL
but	NULL
not	NULL
in	NULL
H-2d	NULL
or	NULL
H-2k	NULL
mice	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

146:3977-3984	NULL
.	NULL

Rawle	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
K.	NULL
A.	NULL
O'Connell	NULL
,	NULL
R.	NULL
W.	NULL
Geib	NULL
,	NULL
B.	NULL
Roberts	NULL
,	NULL
and	NULL
L.	NULL
R.	NULL
Gooding	NULL
.	NULL

1988	NULL
.	NULL

Fine	NULL
mapping	NULL
of	NULL
an	NULL
H-2Kk	NULL
restricted	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
epitope	NULL
in	NULL
SV40	NULL
T	NULL
antigen	NULL
by	NULL
using	NULL
in-frame	NULL
deletion	NULL
mutants	NULL
and	NULL
a	NULL
synthetic	NULL
pep-tide	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

141:2734-2739	NULL
.	NULL

Rawle	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
A.	NULL
E.	NULL
Tollefson	NULL
,	NULL
W.	NULL
S.	NULL
Wold	NULL
,	NULL
and	NULL
L.	NULL
R.	NULL
Gooding	NULL
.	NULL

1989	NULL
.	NULL

Mouse	NULL
anti-adenovirus	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

Inhibition	NULL
of	NULL
lysis	NULL
by	NULL
E3	NULL
gp19K	NULL
but	NULL
not	NULL
E3	NULL
14.7K	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

143:2031-2037	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

J.	NULL
ViRoL	NULL
.	NULL

.	NULL

Shenk	NULL
,	NULL
T.	NULL
1996	NULL
.	NULL

Adenoviridae	NULL
:	NULL
the	NULL
viruses	NULL
and	NULL
their	NULL
replication	NULL
.	NULL

In	NULL
B.	NULL
N.	NULL
Fields	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Virology	NULL
,	NULL
3rd	NULL
ed	NULL
.	NULL

Lippincott-Raven	NULL
Publishers	NULL
,	NULL
Philadelphia	NULL
,	NULL
Pa.	NULL
Sparer	NULL
,	NULL
T.	NULL
E.	NULL
,	NULL
R.	NULL
A.	NULL
Tripp	NULL
,	NULL
D.	NULL
L.	NULL
Dillehay	NULL
,	NULL
T.	NULL
W.	NULL
Hermiston	NULL
,	NULL
W.	NULL
S.	NULL
M.	NULL
Wold	NULL
,	NULL
and	NULL
L.	NULL
R.	NULL
Gooding	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
role	NULL
of	NULL
adenovirus	NULL
early	NULL
region	NULL
3	NULL
proteins	NULL
(	NULL
gp19K	NULL
,	NULL
10.4K	NULL
,	NULL
14.5K	NULL
,	NULL
and	NULL
14.7K	NULL
)	NULL
in	NULL
a	NULL
murine	NULL
pneumonia	NULL
model	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:2431-2439	NULL
.	NULL

Sykuley	NULL
,	NULL
Y.	NULL
,	NULL
M.	NULL
Joo	NULL
,	NULL
I.	NULL
Vturina	NULL
,	NULL
T.	NULL
J.	NULL
Tsomides	NULL
,	NULL
and	NULL
H.	NULL
N.	NULL
Eisen	NULL
.	NULL

1996	NULL
.	NULL

Evidence	NULL
that	NULL
a	NULL
single	NULL
peptide-MHC	NULL
complex	NULL
on	NULL
a	NULL
target	NULL
cell	NULL
can	NULL
elicit	NULL
a	NULL
cytolytic	NULL
T	NULL
cell	NULL
response	NULL
.	NULL

Immunity	NULL
4:565-571	NULL
.	NULL

Takahashi	NULL
,	NULL
H.	NULL
,	NULL
J.	NULL
Cohen	NULL
,	NULL
A.	NULL
Hosmalin	NULL
,	NULL
K.	NULL
B	NULL
.	NULL

Cease	NULL
,	NULL
R.	NULL
Houghten	NULL
,	NULL
J.	NULL
L.	NULL
Cornette	NULL
,	NULL
C.	NULL
DeLisi	NULL
,	NULL
B.	NULL
Moss	NULL
,	NULL
R.	NULL
N.	NULL
Germain	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Berzofsky	NULL
.	NULL

1988	NULL
.	NULL

An	NULL
immunodominant	NULL
epitope	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
envelope	NULL
glycoprotein	NULL
gp160	NULL
recognized	NULL
by	NULL
class	NULL
I	NULL
major	NULL
histocompatibility	NULL
complex	NULL
molecule-restricted	NULL
murine	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:3105-3109	NULL
.	NULL

Tevethia	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
M.	NULL
Lewis	NULL
,	NULL
Y.	NULL
Tanaka	NULL
,	NULL
J.	NULL
Milici	NULL
,	NULL
B.	NULL
Knowles	NULL
,	NULL
W.	NULL
L.	NULL
Maloy	NULL
,	NULL
and	NULL
R.	NULL
Anderson	NULL
.	NULL

1990	NULL
.	NULL

Dissection	NULL
of	NULL
H-2D	NULL
``	NULL
-restricted	NULL
cytotoxic	NULL
T-lymphocyte	NULL
epitopes	NULL
on	NULL
simian	NULL
virus	NULL
40	NULL
T	NULL
antigen	NULL
by	NULL
the	NULL
use	NULL
of	NULL
synthetic	NULL
peptides	NULL
and	NULL
H-2D	NULL
``	NULL
``	NULL
mutants	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:1192-2000	NULL
.	NULL

Thimmappaya	NULL
,	NULL
B.	NULL
,	NULL
C.	NULL
Weinberger	NULL
,	NULL
R.	NULL
J.	NULL
Schneider	NULL
,	NULL
and	NULL
T.	NULL
Shenk	NULL
.	NULL

1982	NULL
.	NULL

Adenovirus	NULL
VAI	NULL
RNA	NULL
is	NULL
required	NULL
for	NULL
efficient	NULL
translation	NULL
of	NULL
viral	NULL
mRNAs	NULL
at	NULL
late	NULL
times	NULL
after	NULL
infection	NULL
.	NULL

Cell	NULL
31:543-551	NULL
.	NULL

Townsend	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
H.	NULL
Bodmer	NULL
.	NULL

1989	NULL
.	NULL

Antigen	NULL
recognition	NULL
by	NULL
class	NULL
I-restricted	NULL
T	NULL
lymphocytes	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

7:601-624	NULL
.	NULL

36a.Tripp	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
and	NULL
L.	NULL
R.	NULL
Gooding	NULL
.	NULL

Unpublished	NULL
data	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

Welsh	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
J.	NULL
Zabner	NULL
,	NULL
S.	NULL
M.	NULL
Graham	NULL
,	NULL
A.	NULL
E.	NULL
Smith	NULL
,	NULL
R.	NULL
Moscicki	NULL
,	NULL
and	NULL
S.	NULL
Wadsworth	NULL
.	NULL

1995	NULL
.	NULL

Adenovirus-mediated	NULL
gene	NULL
transfer	NULL
for	NULL
cystic	NULL
fibrosis	NULL
.	NULL

Part	NULL
A	NULL
.	NULL

Safety	NULL
of	NULL
dose	NULL
and	NULL
repeat	NULL
administration	NULL
in	NULL
the	NULL
nasal	NULL
epithelium	NULL
.	NULL

Part	NULL
B	NULL
.	NULL

Clinical	NULL
efficacy	NULL
in	NULL
the	NULL
maxillary	NULL
sinus	NULL
.	NULL

Hum	NULL
.	NULL

Gene	NULL
Ther	NULL
.	NULL

6205-218	NULL
.	NULL

Yang	NULL
,	NULL
Y.	NULL
,	NULL
H.	NULL
C.	NULL
Ertl	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Wilson	NULL
.	NULL

1994	NULL
.	NULL

MHC	NULL
class	NULL
I-restricted	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
to	NULL
viral	NULL
antigens	NULL
destroy	NULL
hepatocytes	NULL
in	NULL
mice	NULL
infected	NULL
with	NULL
El-deleted	NULL
recombinant	NULL
adenoviruses	NULL
.	NULL

Immunity	NULL
1433-442	NULL
.	NULL

Yang	NULL
,	NULL
Y.	NULL
,	NULL
Q.	NULL
Li	NULL
,	NULL
H.	NULL
C.	NULL
Ertl	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Wilson	NULL
.	NULL

1995	NULL
.	NULL

Cellular	NULL
and	NULL
humoral	NULL
immune	NULL
responses	NULL
to	NULL
viral	NULL
antigens	NULL
create	NULL
barriers	NULL
to	NULL
lung-directed	NULL
gene	NULL
therapy	NULL
with	NULL
recombinant	NULL
adenoviruses	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:2004-2015	NULL
.	NULL

Yang	NULL
,	NULL
Y.	NULL
,	NULL
F.	NULL
A.	NULL
Nunes	NULL
,	NULL
K.	NULL
Berencsi	NULL
,	NULL
E.	NULL
E.	NULL
Furth	NULL
,	NULL
E.	NULL
Gonczol	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Wilson	NULL
.	NULL

1994	NULL
.	NULL

Cellular	NULL
immunity	NULL
to	NULL
viral	NULL
antigens	NULL
limits	NULL
E1-deleted	NULL
adenoviruses	NULL
for	NULL
gene	NULL
therapy	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:4407-4411	NULL
.	NULL

Yang	NULL
,	NULL
Y.	NULL
,	NULL
F.	NULL
A.	NULL
Nunes	NULL
,	NULL
K.	NULL
Berencsi	NULL
,	NULL
E.	NULL
Gonczol	NULL
,	NULL
J.	NULL
F.	NULL
Engelhardt	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Wilson	NULL
.	NULL

1994	NULL
.	NULL

Inactivation	NULL
of	NULL
E2a	NULL
in	NULL
recombinant	NULL
adenoviruses	NULL
improves	NULL
the	NULL
prospect	NULL
for	NULL
gene	NULL
therapy	NULL
in	NULL
cystic	NULL
fibrosis	NULL
.	NULL

Nat	NULL
.	NULL

Genet	NULL
.	NULL

7:362-369	NULL
.	NULL

Yang	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Wilson	NULL
.	NULL

1995	NULL
.	NULL

Clearance	NULL
of	NULL
adenovirus-infected	NULL
hepatocytes	NULL
by	NULL
MHC	NULL
class	NULL
I-restricted	NULL
CD4*	NULL
CTLs	NULL
in	NULL
vivo	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

155:2564-2570	NULL
.	NULL

Zabuer	NULL
,	NULL
J.	NULL
,	NULL
L.	NULL
A.	NULL
Couture	NULL
,	NULL
R.	NULL
J.	NULL
Gregory	NULL
,	NULL
S.	NULL
M.	NULL
Graham	NULL
,	NULL
A.	NULL
E.	NULL
Smith	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Welsh	NULL
.	NULL

1993	NULL
.	NULL

Adenovirus-mediated	NULL
gene	NULL
transfer	NULL
transiently	NULL
corrects	NULL
the	NULL
chloride	NULL
transport	NULL
defect	NULL
in	NULL
nasal	NULL
epithelia	NULL
of	NULL
patients	NULL
with	NULL
cystic	NULL
fibrosis	NULL
.	NULL

Cell	NULL
75:207-216	NULL
.	NULL

Zabner	NULL
,	NULL
J.	NULL
,	NULL
D.	NULL
M.	NULL
Petersen	NULL
,	NULL
A.	NULL
P.	NULL
Puga	NULL
,	NULL
S.	NULL
M.	NULL
Graham	NULL
,	NULL
L.	NULL
A.	NULL
Couture	NULL
,	NULL
L.	NULL
D.	NULL
Keyes	NULL
,	NULL
M.	NULL
J.	NULL
Lukason	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
St	NULL
George	NULL
,	NULL
R.	NULL
J.	NULL
Gregory	NULL
,	NULL
A.	NULL
E.	NULL
Smith	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
.	NULL

Safety	NULL
and	NULL
efficacy	NULL
of	NULL
repetitive	NULL
adenovirus-mediated	NULL
transfer	NULL
of	NULL
CFTR	NULL
cDNA	NULL
to	NULL
airway	NULL
epithelia	NULL
of	NULL
primates	NULL
and	NULL
cotton	NULL
rats	NULL
.	NULL

Nat	NULL
.	NULL

Genet	NULL
.	NULL

6:75-83	NULL
.	NULL

Zhang	NULL
,	NULL
X.	NULL
L.	NULL
,	NULL
A.	NULL
J.	NULL
Bellett	NULL
,	NULL
R.	NULL
T.	NULL
Ha	NULL
,	NULL
A.	NULL
W.	NULL
Braithwaite	NULL
,	NULL
and	NULL
A.	NULL
Mullbacher	NULL
.	NULL

1991	NULL
.	NULL

Adenovirus	NULL
type	NULL
5	NULL
E3	NULL
gene	NULL
products	NULL
interfere	NULL
with	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
cytolytic	NULL
T	NULL
cell	NULL
immunodominant	NULL
Ela	NULL
antigen	NULL
.	NULL

Virology	NULL
180:199-206	NULL
.	NULL

